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ABSTRACT OF DISSERTATION 
 
 
 
A PREDICTIVE PROBABILITY INTERIM DESIGN FOR PHASE II CLINICAL 
TRIALS WITH CONTINUOUS ENDPOINTS 
 
Phase II clinical trials aim to potentially screen out ineffective and identify effective 
therapies to move forward to randomized phase III trials. Single-arm studies remain the 
most utilized design in phase II oncology trials, especially in scenarios where a randomized 
design is simply not practical. Due to concerns regarding excessive toxicity or ineffective 
new treatment strategies, interim analyses are typically incorporated in the trial, and the 
choice of statistical methods mainly depends on the type of primary endpoints. For 
oncology trials, the most common primary objectives in phase II trials include tumor 
response rate (binary endpoint) and progression disease-free survival (time-to-event 
endpoint). Interim strategies are well-developed for both endpoints in single-arm phase II 
trials.  
The advent of molecular targeted therapies, often with lower toxicity profiles from 
traditional cytotoxic treatments, has shifted the drug development paradigm into 
establishing evidence of biological activity, target modulation and pharmacodynamics 
effects of these therapies in early phase trials. As such, these trials need to address 
simultaneous evaluation of safety as well as proof-of-concept of biological marker activity 
or changes in continuous tumor size instead of binary response rates.  
In this dissertation, we extend a predictive probability design for binary outcomes 
in the single-arm clinical trial setting and develop two interim designs for continuous 
endpoints, such as continuous tumor shrinkage or change in a biomarker over time. The 
two-stage design mainly focuses on the futility stopping strategies, while it also has the 
capacity of early stopping for efficacy. Both optimal and minimax designs are presented 
for this two-stage design. The multi-stage design has the flexibility of stopping the trial 
early either due to futility or efficacy. Due to the intense computation and searching 
strategy we adopt, only the minimax design is presented for this multi-stage design. The 
multi-stage design allows for up to 40 interim looks with continuous monitoring possible 
for large and moderate effect sizes, requiring an overall sample size less than 40. The 
stopping boundaries for both designs are based on predictive probability with normal 
likelihood and its conjugated prior distributions, while the design itself satisfies the pre-
specified type I and type II error rate constraints. From simulation results, when compared 
with binary endpoints, both designs well preserve statistical properties across different 
effect sizes with reduced sample size. We also develop an R package, PPSC, and detail it 
in chapter four, so that both designs can be freely accessible for use in future phase II 
clinical trials with the collaborative efforts of biostatisticians. Clinical investigators and 
  
biostatisticians have the flexibility to specify the parameters from the hypothesis testing 
framework, searching ranges of the boundaries for predictive probabilities, the number of 
interim looks involved and if the continuous monitoring is preferred and so on.   
 
KEYWORDS: Predictive Probability, Continuous Endpoints, Single-Arm, Phase II Trials, 
Interim Strategy, R package 
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CHAPTER ONE 
Introduction  
1.1 Current Endpoints in Oncology Phase II Clinical Trials 
In oncology clinical trials, overall survival (OS) has been the gold standard, and 
considered to be the most clinically relevant and reliable primary endpoint for definitive 
phase III randomized clinical trials. Therefore, a good endpoint that can predict the overall 
survival effectively in phase II trials is vital in drug development. In practice, tumor 
shrinkage is divided into the response rate (RR) according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria, with a cut-off  value of 30%. Both response 
rate and progression-free survival (PFS) are commonly used as surrogate endpoints for 
efficacy in current phase II trials [1, 2].  
One of the major challenges in drug development is the efficient design of phase II 
trials to identify active compounds for phase III testing. The failure to accurately predict 
effective drugs/treatments in early phase trials causes a disproportionately high incidence 
of phase III trials with negative results. It has been reported that only 5% of treatments 
tested in the phase III setting are approved in oncology [2]. Therefore, there is a need to 
screen agents in the phase II setting quickly and effectively, while using more robust 
endpoints predictive of overall survival (OS) and clinical benefit that will predict phase III 
success, and balance resources to prioritize those therapies deemed promising, especially 
for novel therapeutics or targeted agents. Endpoints to consider include: continuous tumor 
size, quality of life outcomes, molecular biomarkers, and imaging assessment [3, 4].  
Since trial design, sample size consideration, analysis plans and interim properties 
completely depend on the type of outcome variable selected, choice of endpoints is of great 
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importance before the trial starts. In terms of oncology trials, although response rate has 
been widely used in practice, studies have shown that designs using binary response rate 
require many more patients than those using continuous tumor size shrinkage, and lead to 
loss of statistical efficiency [5, 6]. In addition, drugs can be still active even if they do not 
lead to a high-level of tumor regression; thus, in this case, a change in a biomarker over 
time might be more helpful. Further, previous studies have shown that for specific types of 
cancer, such as patients with metastatic renal cell carcinoma and treated with target 
therapies, early primary tumor size reduction, which is about 10% tumor shrinkage, is an 
independent predictor of improved overall survival. In these situations, RECIST criteria 
may not be appropriate [1]. Therefore, using continuous tumor size as the primary endpoint 
has been investigated and shown to be potentially clinically beneficial [7, 8].  
 
1.2 Importance of Single-Arm Trials 
Although randomized phase II trials, including but not limited to selection designs, 
screening designs, and randomized discontinuation designs, are gaining popularity with 
clinical researchers, single-arm studies still remain the most utilized design in phase II 
oncology trials, especially in scenarios where a randomized design is simply not practical 
[9-11]. Those scenarios include a low likelihood of response to standard therapies, the 
mechanism of action expected to be cytotoxic, the desired effect size being large, and 
historical controls remaining stable over time. In particular, with the development of 
molecular target therapies in oncology recent years, single-arm trials still remain the most 
feasible design to conduct in practice, especially for smaller centers or investigator initiated 
trials when the science is novel, and it would be otherwise impossible with available 
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resources to obtain preliminary data to then justify a larger, multi-center trial. These 
situations are quite common for rare tumors or subtypes and gynecologic cancers [12, 13].  
 
1.3 Current Phase II Trial Designs 
1.3.1 Importance of Interim Strategies in the Trial  
Interim strategies are of great importance in each stage of oncology clinical trials. 
Developed to protect participants from unsafe drugs or to hasten the general 
implementation of a beneficial therapy, interim strategies can be utilized to stop trials early 
either for safety, futility, or efficacy [14]. In addition, interim monitoring in the trial 
can help identify the need to collect additional data in order to clarify questions of 
clinical benefit or safety issues that may arise during the trial. It can further help reveal 
logical problems or issues involving data quality that need to be promptly addressed. Thus, 
incorporating appropriate interim strategies in the trials will facilitate the success of the 
trial and benefit patients, as well as save time and resources [15-17]. In particular, for phase II 
trials, which usually have a smaller sample size and relatively short in duration, enough 
information must be obtained to decide whether the trials should be stopped for lack of 
evidence suggesting safety or efficacy, or whether the trials should be continued and moved 
forward to confirmatory phase III testing for evidence demonstrating efficacy. An 
appropriate stopping rule can lead quickly to an indication and facilitate the decision 
making. 
1.3.2 Frequentist Designs for Binary Outcome 
During past decades, many statistical methods have been proposed and developed 
for phase II trial designs. Gehan proposed a two-stage design, in which early termination 
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depends on the number of responses in the first stage. If there is no response at the end of 
the first stage, the trial is stopped for futility; otherwise, continue to the second stage [18]. 
Simon developed both optimal and minimax design for a single-arm two-stage setting [19], 
which has been the most widely used single-arm design for phase II studies with binary 
outcomes. Simon’s two-stage design has been extended and developed into different 
directions in the literature and practice. In particular, Chen extended Simon’s design into a 
three-stage design that allows early termination of the trial due to futility and 10% average 
sample size reduction when compared to the two-stage design [20]. Bryant and Day 
incorporated toxicity into the design to monitor both efficacy and toxicity simultaneously 
[21], which was then extended into both two-stage and multi-stage designs for dependent 
variables and control of the type I/II error rates at the same time [22, 23]. Lin et al. extended 
Simon’s design into a two-stage setting that can utilize both primary and secondary 
endpoints, both of which are assumed to be binary outcomes [24]. Jung et al. developed a 
graphical method to search for a compromise between optimal and minimax designs [25]. 
Since two-stage designs are still the most widely used in practice for early phase II trials, 
especially with the popularity of Simon’s two-stage design, we detail the Simon’s two-
stage design below. 
Simon’s two-stage design 
Simon's two-stage design for terminating the trial early due to futility has been the 
most commonly applied design in single-arm cancer clinical trials [19]. The design can be 
illustrated in Figure 1.1. In his design, the primary endpoint is the binary response rate. 
During the first stage, 𝑛1 patients are enrolled. If the number of patients with responses 
within these 𝑛1 patients is less than or equal to 𝑟1, the trial should be terminated early for 
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futility. Otherwise, we should move forward to the second stage and enroll additional 
𝑛2 patients. If the number of responses at the second stage is less than 𝑟2, we should stop 
the trial and claim that this new therapy is not effective and not worth further investigating. 
𝑟1 and 𝑟2 are the critical values for the number of responses at the end of each stage . 
Mathematically, let the true probability of response be 𝑝, which follows a binomial 
distribution. Let 𝑝 ≤ 𝑝0  represents the drug/therapy with low activity that should be 
screened out from further testing, and 𝑝 ≥ 𝑝1  represents a drug/therapy with sufficient 
activity to warrant further phase III testing. 𝑝0 is some uninteresting level of response rate 
and 𝑝1 is a desirable target level.  A typical hypothesis testing can be stated:  
𝐻0: 𝑝 ≤ 𝑝0 vs. 𝐻1: 𝑝 ≥ 𝑝1 
Let X denote the number of responses at the 1st stage. 
1. If the drug is rejected at the end of the 1st stage, the total number of responses at 
the end of the 1st stage is less than 𝑟1. Thus, the probability of rejecting a drug (failing to 
reject the null hypothesis) with response probability 𝑝 is: 
Pr(𝑋 ≤ 𝑟1) =  ∑𝑏(𝑥; 𝑝, 𝑛1)
𝑟1
𝑥=0
= 𝐵(𝑟1; 𝑝, 𝑛1) 
where 𝑏(𝑥; 𝑝, 𝑛1) is the probability mass function (pmf) of the binomial distribution with 
parameters 𝑝 and 𝑛1. 𝐵(𝑟1; 𝑝, 𝑛1) is the cumulative distribution function (𝑐𝑑𝑓) of binomial 
distribution representing Pr(𝑋 ≤ 𝑟1) with parameters 𝑝 and 𝑛1.  
2. If the drug is rejected at the end of the 2nd stage, then the total number of 
responses in the 2nd stage is less than 𝑟2, and the probability of rejecting the drug  can be 
expressed as:  
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∑ 𝑏(𝑥; 𝑝, 𝑛1)
min (𝑟,𝑛1)
𝑥=𝑟1+1 
 𝐵(𝑟 − 𝑥; 𝑝, 𝑛2) 
Therefore, the probability of rejecting the drug, 𝑃𝑟(reject the drug |  𝑝, 𝑛1, 𝑛2, 𝑟1, ), with 
response probability 𝑝 can be expressed as:  
𝐵(𝑟1; 𝑝, 𝑛1) + ∑ 𝑏(𝑥; 𝑝, 𝑛1)
min (𝑟,𝑛1)
𝑥=𝑟1+1 
 𝐵(𝑟 − 𝑥; 𝑝, 𝑛2) 
The first part of the formula above is the probability of failing to reject the null hypothesis 
at the end of the 1st stage, and the second part of the formula above is the probability of 
failing to reject the null hypothesis at the end of 2nd stage.  
Thus, the type I and type II error can be calculated as follows: 
𝛼 = 1 − 𝑃𝑟(reject the drug | 𝑝0, 𝑛1, 𝑛2, 𝑟1, 𝑟2 ) 
𝛽 = 𝑃𝑟(reject the drug | 𝑝1, 𝑛1, 𝑛2, 𝑟1, 𝑟2) 
The probability of early termination [𝑃𝐸𝑇 =  𝐵(𝑟1; 𝑝, 𝑛1)] and the expected sample size 
under the null hypothesis is  
𝐸(𝑁) =  𝑛1 + (1 − 𝑃𝐸𝑇)𝑛2 
In Simon’s two-stage design paper, both optimal and minimax designs were 
introduced [19]. The optimal design is defined to minimize the average sample size under 
the null hypothesis, while the minimax design is simply to minimize the total sample size 
required for the two stages. Both designs satisfy the pre-specified nominal type I and type 
II error rates.  
1.3.3 Bayesian Designs for Binary Outcome 
Bayesian approaches, which make inferences about the unknown parameters of 
interest based on observed data from realized sample, have gained popularity during the 
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past decades. Compared with frequentist approaches, Bayesian approaches can be 
appealing as they incorporate information before and during a trial to design and monitor 
progress [26, 27].  
In terms of phase II clinical trial designs, especially the interim designs, there has 
been vast development in the Bayesian framework. In particular, Thall and Simon 
introduced a class of phase II Bayesian clinical trial interim designs [28]. Tan and Machin 
proposed a two-stage design based on the posterior distribution [29]. Their design was then 
extended into a two-stage design based on predictive distribution [30-32]. Mayo and 
Gajewski utilized informative conjugate priors to assess the sample size calculation in the 
Bayesian setting [33]. Wang et al. developed a Bayesian single-arm two-stage design 
incorporating both frequentist and Bayesian error rates [34]. Shi and Yin proposed a two-
stage design with switching hypothesis, in which the first stage is a single-arm study, while 
the second stage is a two-arm study; the design controls both frequentist and Bayesian error 
rates [35]. 
Predictive probabilities (PP) approach for clinical trial designs was originally 
introduced by Herson for binary endpoints, but did not control the type I and type II error 
rates throughout the trial [36]. Lee and Liu developed a Bayesian alternative based on PP 
for binary response rate endpoints [37]. Their PP design allows for continuous monitoring 
at pre-specified intervals, is efficient in stopping a trial early if the intervention is not 
efficacious, and controls type I and II error rates. Their design was then extended into a 
randomized setting by Yin et al. for binary endpoints [38].  Dong et al. incorporated the 
Bayesian error rates into Lee and Liu’s PP design and developed a two-stage single-arm 
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design for binary endpoints [39]. Since our design is a straightforward extension to Lee 
and Liu’s PP design, their design is detailed below.  
Lee and Liu’s Predictive Probability Design 
Oftentimes, when we do not have sufficient data to obtain a definitive conclusion, 
we need to figure out if the trend continues, the probability of reaching a conclusive result 
by the end of the study. Lee and Liu developed an efficient and flexible design 
incorporating the properties of predictive probability under Bayesian framework [37]. 
Under the same hypothesis testing framework, 
𝐻0: 𝑝 ≤ 𝑝0 vs. 𝐻1: 𝑝 ≥ 𝑝1 
At any stage, let 𝑋 denote the number of responses in the current 𝑛 patients, which follows a 
binomial distribution with parameters 𝑛 and 𝑝. Thus, the likelihood function for the observed 
data 𝑥 is 
𝐿𝑥(𝑝) =  𝑝
𝑥(1 − 𝑝)𝑛−𝑝 
We assume the prior distribution of the response rate 𝜋(𝑝)  follows a beta 
distribution, 𝑏𝑒𝑡𝑎(𝑎0, 𝑏0) , which is a conjugate prior for the binomial distribution 
representing the investigator's previous knowledge or belief of the efficacy of the new agent. 
The prior mean is 𝑎0/ (𝑎0 + 𝑏0),  with (𝑎0 + 𝑏0) to be considered as a measure of the 
amount of information contained in the prior. 𝑎0 and 𝑏0 can be considered as the number 
of responses and the number of non-responses, respectively. Thus, the posterior 
distribution of the response rate follows a beta distribution 𝑏𝑒𝑡𝑎(𝑎0 + 𝑥, 𝑏0 + 𝑛 − 𝑥).  
Therefore, the number of responses in the potential future 𝑚 =  𝑁𝑚𝑎𝑥 −  𝑛 
patients, 𝑌 , follows a beta-binomial distribution, where 𝑁𝑚𝑎𝑥 is a maximum accrual of 
patients,  
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𝑏𝑒𝑡𝑎 −  𝑏𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑚; 𝑎0  +  𝑥;  𝑏0  +  𝑛 −  𝑥) 
The posterior probability of 𝑃 when 𝑌 =  𝑖; 𝑋 =  𝑥 can be written as 
𝑏𝑒𝑡𝑎(𝑎0  +  𝑥 +  𝑖;  𝑏0  +  𝑁𝑚𝑎𝑥 −  𝑥 −  𝑖), 
giving  
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑃𝑃) =∑𝑃𝑟𝑜𝑏(𝑌 =  𝑖|𝑥)
𝑚
𝑖=0
∗ 𝐼(𝑃𝑟𝑜𝑏(𝑃 ≥ 𝑝0|𝑥, 𝑌 = 𝑖) ≥ 𝑃𝑇)
=  ∑(𝑃𝑟𝑜𝑏(𝑌 =  𝑖|𝑥)
𝑚
𝑖=0
∗ 𝐼(𝐵𝑖 ≥  𝑃𝑇)) =  ∑(𝑃𝑟𝑜𝑏(𝑌 =  𝑖|𝑥)
𝑚
𝑖=0
∗ 𝐼𝑖) 
where 𝐵𝑖 =  𝑃𝑟𝑜𝑏(𝑃 ≥ 𝑝0|𝑥, 𝑌 = 𝑖), which measures the probability that the response 
rate is larger than 𝑝0 given 𝑥 responses in 𝑛 patients in the current data, and 𝑖 patients in 
the 𝑚 future patients; and 𝑃𝑟𝑜𝑏(𝑌 =  𝑖|𝑥)is the probability of observing 𝑖 responses in 𝑚 
patients given current data 𝑥, where 𝑌 follows a beta-binomial distribution. 
Choose 𝜃𝐿 as a small positive number and 𝜃𝑈 as a large positive number, between 0 and 1. 
      If 𝑃𝑃 ≤ 𝑃𝐿 then stop the trial and claim the drug is not promising; 
      If 𝑃𝑃 ≥ 𝑃𝑈 then stop the trial and reject the null hypothesis; 
      Otherwise, continue to the next stage until reaching the maximum sample size. 
Meanwhile, Lee and Liu’s PP design also meets the pre-specified frequentist type I and II 
error rates. By summing up the probability of rejecting the null hypothesis at each stage, 
the actual type I and type II error can be calculated. 
1.3.4 Bayesian vs. Frequentist Approaches  
 Two statistical philosophies dominate trial designs and analyses. The frequentist 
approach centers on the idea that data is a repeatable random sample of the true population 
and underlying parameters are fixed and constant. Studies are designed to meet pre-
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specified type I and type II errors, and decisions are based on point estimates, standard 
errors, and 95% confidence intervals [40, 41]. The Bayesian approach observes fixed data 
from the realized sample, and parameters are unknown and need to be described 
probabilistically. Bayesian studies start with a prior distribution based on previous studies 
or historical rates, and make decisions based on accrued data with an updated posterior 
distribution using means, quantiles, and posterior probabilities [42, 43]. 
There are many reviews and editorials discussing the controversies surrounding 
these two approaches; however, there is no argument that both of these strategies are 
implemented in clinical trials today [44-47]. Frequentist approaches have historically been 
the more popular strategy with designed a priori stopping rules and number of allowed 
looks at the data. Some may consider these rules inflexible, but many favor this approach 
as it allows for a more final yes/no decision at the conclusion of a study [48]. It also does 
not require sophisticated computer programs or simulations to conduct these tests. Some 
Bayesian approaches can be appealing as they incorporate information before and during 
a trial to design and monitor progress respectively [26, 27, 37, 49, 50]. 
There is generally more flexibility and consistency for making inferences; however, 
these approaches often require more computer programming, can be complex to implement 
without resources and staff knowledgeable in these methods, and face challenges with 
scientific and regulatory review panels without sufficient justification of design choice [51, 
52]. 
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1.3.5 Designs for Continuous Endpoints  
Frequentist Designs for Continuous Endpoints 
As mentioned above, using response rate endpoints will lead to loss of statistical 
efficiency. Therefore, previous studies have proposed using continuous tumor shrinkage as 
the primary endpoint. It was originally proposed by Lavin [53], which was a single-arm 
and single stage design. His work was then extended into a two-arm randomized design 
with no planned interim analysis [54]. Wason et al. proposed a frequentist two-stage design 
based on continuous tumor shrinkage and claimed that there was a 37% reduction in sample 
size [5]. Their group also developed a randomized multi-stage 𝛿 -minimax design for 
continuous outcomes [55]. Hsiao et al. also proposed a frequentist two-stage design based 
on continuous efficacy endpoints, using a general quasi-Newton optimizer to find the 
optimal design [56]. Other studies using continuous endpoints, especially in a randomized 
scenario, have also been proposed in the literature. In particular, Whitehead developed a 
two-stage randomized design with normally distributed endpoints, and the trial decision 
rule was based on a normalizing transformed p-value [57]. Their study was then extended 
into a randomized two-stage design that can minimize the maximum expected sample size 
across all possible treatment effects [58]. 
Bayesian Designs for Continuous Endpoints 
In the Bayesian Framework, Brutti et al. proposed a Bayesian approach based on 
posterior distribution with a class of prior distribution to determine the same size of 
sequential designs [59]. Their group also proposed a Bayesian two-stage design for 
continuous endpoints using design priors and analysis priors [32]. The design prior is to 
help plan the trial under expected scenarios, and the analysis prior is to represent the prior 
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knowledge of the parameter being studied. In a randomized two-arm trial setting, 
Dmitrienko and Wang discussed the stopping rules incorporating Bayesian predictive 
approach in terms of normally distributed outcome. They also compared purely Bayesian 
predictive probability approach with frequentist as well as mixed Bayesian-frequentist 
methods, such as conditional and predictive power stopping rules [60].  
On the other hand, group sequential designs play an important role in current multi-
stage clinical trials practice. When compared to single-stage designs, multi-stage designs 
have the advantage that the information obtained from the interim data can be incorporated 
into the design, which makes it more efficient and stops the trial early. Fleming proposed 
a multiple testing procedure for one-sample design to allow for early termination while 
maintain the statistical properties for binary endpoints[61]. Pocock’s design as well as 
O’Brien and Fleming’s design are still the two most commonly used group-sequential 
options [62, 63]. 
To our knowledge, there has not been any published Bayesian predictive work 
while preserving frequentist properties, focusing on a single-arm setting for continuous 
outcomes. As an example of continuous endpoints, tumor size change has been discussed 
to be a potential biomarker for predicting survival in early phase trials [64]. Sometimes, 
when tumor does not have a high level of shrinkage, and there is a biomarker associated 
with the treatment effect, the continuous change in this biomarker will be a more 
appropriate endpoint. Further, design based on continuous biomarkers offers greater 
statistical power than a categorical endpoint, since dividing the continuous endpoints into 
categorical variables leads to loss of statistical efficiency. Therefore, there is a need to 
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develop interim strategies to incorporate continuous endpoints to accommodate these novel 
biomarker endpoints.  
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Figure 1.1 Flowchart of Simon’s two-stage design 
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CHAPTER TWO 
A Two-Stage Predictive Probability Interim Design for Phase II Clinical Trials with 
Continuous Endpoints 
2.1 Abstract 
Molecular targeted therapies often come with lower toxicity profiles than 
traditional cytotoxic treatments, thus shifting the drug development paradigm into 
establishing evidence of biological activity, target modulation and pharmacodynamics 
effects in early phase trials. Therefore, these trials need to address simultaneous evaluation 
of safety, proof-of-concept biological marker activity or changes in continuous tumor size 
instead of binary response rate. Interim analyses are typically incorporated in the trial due 
to concerns regarding excessive toxicity and ineffective new treatment. There is a lack of 
interim strategies developed to monitor futility and/or efficacy for these types of 
continuous outcomes, especially in single-arm phase II trials. We propose a two-stage 
design based on predictive probability to accommodate continuous endpoints, using 
continuous tumor shrinkage as an example and assuming a normal distribution with known 
variance. Although the design is primarily for early termination due to futility, it also has 
the capacity to stop the trial early for efficacy. Simulation results and the case study 
demonstrated that the proposed design can incorporate an interim stop for futility while 
maintaining desirable design properties. As expected, using continuous tumor size change 
resulted in reduced sample sizes for both optimal and minimax designs. A limited 
exploration of various priors was performed and shown to be robust. As research rapidly 
moves to incorporate more molecular targeted therapies, this design will accommodate new 
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types of outcomes while allowing for flexible stopping rules to continue optimizing trial 
resources and prioritizing agents with compelling early phase data. 
Keywords: Phase II trials; single-arm; continuous endpoints; predictive probability; 
interim 
 
2.2 Introduction 
Phase II clinical trials aim to potentially screen out ineffective, and identify 
effective therapies to move forward to the randomized phase III setting. Although 
randomized phase II trials, including but not limited to selection designs, screening designs, 
and randomized discontinuation designs, are gaining popularity with clinical researchers, 
single-arm studies still remain the most utilized design in phase II oncology trials, 
especially in scenarios where a randomized design is simply not practical [9-11]. These 
can include a low likelihood of response to standard therapies, the mechanism of action is 
expected to be cytotoxic, the desired effect size is large, and historical controls remain 
stable over time. Further, given the shifting molecular landscape in oncology, smaller 
single-arm trials are most feasible to conduct in terms of targeted therapeutic agents, 
especially for smaller centers or investigator initiated trials when the science is novel. It 
would be otherwise impossible with available resources to obtain preliminary data to then 
justify a larger, multi-center trial. The single-arm trials are also feasible for rare tumors or 
subtypes, such as NSCLC patients with ERBB2 or BRAF alteration and gynecologic 
cancers [12, 65].  
Due to concerns regarding excessive toxicity and/or ineffective new treatment 
strategies, interim analyses are encouraged and typically incorporated. The choice of 
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statistical methods depends on the type of primary endpoint. For oncology studies, the most 
common way of assessing tumor shrinkage is to dichotomize patients by response rate 
according to RECIST [1]. Accordingly, Simon’s two-stage design is the most widely used 
design for this binary endpoint in single-arm trials [19], which allows for one early stop 
due to futility. There are many extensions of Simon’s design, including composite 
endpoints or multiple interim looks [20, 21].  However, studies have shown that using 
binary response rate, besides loss of statistical efficiency, more patients are required than 
those using continuous tumor size shrinkage and drugs can be active even if they do not 
lead to high-levels of tumor regression [5, 6].  
Besides tumor size changes, continuous outcomes could also include biomarker 
changes over time from baseline as preliminary evidence of biologic mechanism. Examples 
include but are not limited to measuring proliferation by Ki67, apoptosis, genetic 
alterations, or immunity measures of cytokines or TNF-alpha. Detected in circulation, 
excretion or biopsies, these biomarkers must be robust and clinically validated, especially 
if utilized as a primary outcome [66]. Thus, RECIST may not be appropriate in such 
circumstances and using continuous tumor size as primary outcome has been investigated 
and shown to be potentially clinical beneficial [8].  
The idea of using continuous tumor size changes as primary endpoint, was 
originally proposed by Lavin [53], with his work extended into a two-arm randomized 
single-stage design with no interim considerations [54]. Wason et al. extended the 
frequentist Simon’s two-stage design for continuous outcomes under normal distribution 
assumptions [5]. He compared the optimal and minimax designs for continuous tumor size 
reduction, claiming that using continuous endpoints resulted in lower expected and 
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maximum sample sizes as compared to binary counterparts. Hsiao et al. also proposed a 
frequentist two-stage design based on continuous efficacy endpoints, using a general quasi-
Newton optimizer to find the optimal design [56]. Bayesian interim strategies involving 
binary endpoints have been extensively studied [28, 29]. In terms of normally distributed 
outcomes, the predictive probability approach for Bayesian interim strategies has been 
proposed only in a randomized setting [60].  
In this paper, we extend Lee and Liu’s PP design for continuous endpoints in the 
single-arm trial setting.  For purposes of illustration, we use continuous tumor size change 
as an example of a continuous clinical endpoint, as it has been discussed as a potential 
surrogate for survival in early phase trials. However, this design would be applicable for 
any continuous outcome [64].  In section 2.3, we provide explicit formulae for the 
continuous PP design optimization criteria. In section 2.4, we report simulation results with 
a case study and conclude with a discussion in section 2.5.   
 
2.3 Methods 
2.3.1 Notation and Proposed Design 
In a phase II trial with continuous endpoints, the hypothesis testing framework can be 
described as follows: 
𝐻0: 𝜇 ≤  𝜇0  vs. 𝐻1: 𝜇 ≥  𝜇1 
where 𝜇0 represents some maximum uninteresting efficacy threshold or efficacy from the 
standard treatment, and  𝜇1 represents a target efficacy threshold from a new treatment 
that would warrant additional study. A trial is usually designed such that  
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𝑃(𝐴𝑐𝑐𝑒𝑝𝑡 𝑁𝑒𝑤 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡|𝐻0) ≤ 𝛼 
𝑃(𝑅𝑒𝑗𝑒𝑐𝑡 𝑁𝑒𝑤 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡|𝐻1) ≤ 𝛽 
where 𝛼 and 𝛽 represent type I and type II error rate constraints.  
The proposed extension of Lee and Liu's PP design for continuous endpoints is 
described in Figure 2.1. For notation purposes, we define the percentage decrease in the 
sum of the longest diameter of the target lesions compared to baseline as “tumor size 
change” and assume it is normally distributed with mean 𝜇 and variance 𝜎2, where 𝜎2 is 
assumed to be known. Positive values of 𝜇  represent shrinkage in the tumor size. We 
choose a normal conjugate prior distribution 𝑁(𝜃, 𝜏2)  for 𝜇 , which represents the 
investigator’s previous knowledge of the tumor size change from standard treatment or 
historical control. We also define the effective sample size for the prior (ESS) as  
𝜎2
𝜏2
, 
according to previous literature [67]. ESS can be understood as the amount of information 
and weight contained in the prior. We set the maximum accrual of patients to 𝑁𝑚𝑎𝑥. The 
number of patients in the first stage is 𝑛1 and in the second stage is 𝑛2, where 𝑛1 + 𝑛2 =
 𝑁𝑚𝑎𝑥.  After recruiting 𝑛1 patients in the first stage, the mean percentage change of the 
tumor size from these 𝑛1 patients is denoted as ?̅?𝑛1 . Thus, the corresponding posterior 
distribution on 𝜇 is normally distributed with  
𝐸(𝜇|𝑥1, 𝑥2, … , 𝑥𝑛1) =  
𝜎2𝜃
𝑛1𝜏2 + 𝜎2
+ 
𝑛1𝜏
2
𝑛1𝜏2 + 𝜎2
?̅?𝑛1 
𝑉𝑎𝑟(𝜇|𝑥1, 𝑥2, … , 𝑥𝑛1) =  
𝜏2𝜎2
𝑛1𝜏2 + 𝜎2
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Further, if we were to observe the future 𝑛2 patients, the new posterior distribution of the 
tumor size change, 𝜇∗, follows a normal distribution with the mean 𝜇𝑝
∗  and 𝜎𝑝
∗2, where  
𝜇𝑝
∗ = 
𝜎2𝜃
(𝑛1 + 𝑛2)𝜏2 + 𝜎2
+ 
𝑛1𝜏
2
(𝑛1 + 𝑛2)𝜏2 + 𝜎2
?̅?𝑛1 +
𝑛2𝜏
2?̅?𝑛2
(𝑛1 + 𝑛2)𝜏2 + 𝜎2
 
𝜎𝑝
∗2 = 
𝜏2𝜎2
(𝑛1 + 𝑛2)𝜏2 + 𝜎2
 
Similar to Lee and Liu's PP design, we define 𝐵𝑖 = 𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛1 , ?̅?𝑛2). 𝐵𝑖 measures 
the probability that the mean tumor size change is larger than 𝜇0, given the mean tumor 
size change in current 𝑛1 patients and future 𝑛2 patients. Comparing 𝐵𝑖 to a threshold 𝑃𝑇, 
we aim to conclude the treatment is efficacious when 𝐵𝑖 > 𝑃𝑇,  
𝐵𝑖 =  𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛1 , ?̅?𝑛2) = 1 − 𝑃𝑟𝑜𝑏(𝜇∗ ≤ 𝜇0|?̅?𝑛1 , ?̅?𝑛2) 
= 1 −  𝛷 (
𝜇0− 𝜇𝑝
∗
𝜎𝑝
∗ ) > 𝑃𝑇  
where 𝛷 (.) represents the cumulative density function (CDF) of the standard normal 
distribution. The above inequality (1) can be derived into an inequality of ?̅?𝑛2 regarding 
𝑃𝑇.  
?̅?𝑛2 >
((𝑛1 + 𝑛2)𝜏
2 + 𝜎2) (𝜇0 − 𝜎𝑝
∗𝛷−1(1 − 𝑃𝑇)) − 𝜎
2𝜃 − 𝜏2𝑛1?̅?𝑛1
𝑛2𝜏2
= 𝛿 
The posterior predictive distribution of tumor size change from the future 𝑛2 patients 
follows a normal distribution 𝑁(𝜇𝑝, 𝜎𝑝
2), where  
𝜇𝑝 = 
𝜎2𝜃
𝑛1𝜏2 + 𝜎2
+ 
𝑛1𝜏
2
𝑛1𝜏2 + 𝜎2
?̅?𝑛1 
(1) 
(2) 
 21 
 
𝜎𝑝
2 = 
𝜎2
𝑛2
+ 
𝜏2𝜎2
𝑛1𝜏2 + 𝜎2
 
 
 
Then we define 
Predictive probability (𝑃𝑃) = 𝑃𝑟𝑜𝑏(?̅?𝑛2 > 𝛿|?̅?𝑛1) 
= 1 − 𝑃𝑟𝑜𝑏((?̅?𝑛2 ≤ 𝛿|?̅?𝑛1) = 1 −  𝛷 (
𝛿 − 𝜇𝑝 
𝜎𝑝
)  
𝑃𝑃 is a measurement that can be used to determine whether the trial should be 
stopped early either due to efficacy or futility, or whether the trial should be continued 
given current inclusive data. A high PP means that given current data, the treatment is 
likely to be promising by the end of the study; whereas a low PP suggests that the treatment 
may not have sufficient activity.  
2.3.2 Trial Decision Rules 
We use similar decision rules as those described in Lee and Liu’s PP design. 𝑃𝐿 and 
𝑃𝑈  are defined as lower and upper bounds for the predictive probability, respectively. 
Usually, 𝑃𝐿 is chosen as a small positive number and 𝑃𝑈 is a large positive number, both 
of which are between 0 and 1. If 𝑃𝑃 is less than a small 𝑃𝐿 , it indicates that it is unlikely 
that the true mean will be larger than 𝜇0 at the end of the trial given the information from 
the patients in the first stage. Alternatively, if 𝑃𝑃 is greater than a large 𝑃𝑈 , it means that 
it is very possible that we can claim the test drug or treatment is effective at the end of the 
trial based on current data. The decision rules in terms of 𝑃𝑃 are:  
(3) 
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 If  𝑃𝑃 <  𝑃𝐿, stop the trial early for futility; 
 If  𝑃𝑃 >  𝑃𝑈, stop the trial early for efficacy; 
 Otherwise, continue to enroll patients to the next stage.  
By comparing 𝑃𝑃 with 𝑃𝐿 and 𝑃𝑈 and solving for ?̅?𝑛1, we can obtain ?̅?𝐿 and ?̅?𝑈, 
which are defined as the lower and upper bounds for the sample mean from patients in 
the first stage , ?̅?𝑛1, respectively.  
?̅?𝐿 = 
𝑘1𝑘2𝜇0 − 𝑘1𝑘2𝜎𝑝
∗𝛷−1(1 − 𝑃𝑇) − 𝑛2𝜏
2𝑘2(𝜎𝑝𝛷
−1(1 − 𝑃𝐿))
𝑘2 + 𝑛2𝜏2
− 𝜎2𝜃
𝑛1𝜏2
 
 
?̅?𝑈 = 
𝑘1𝑘2𝜇0 − 𝑘1𝑘2𝜎𝑝
∗𝛷−1(1 − 𝑃𝑇) − 𝑛2𝜏
2𝑘2 (𝜎𝑝𝛷
−1(1 − 𝑃𝑈))
𝑘2 + 𝑛2𝜏2
− 𝜎2𝜃
𝑛1𝜏2
 
where 𝑘1 = (𝑛1 + 𝑛2)𝜏
2 + 𝜎2, 𝑘2 = 𝑛1𝜏
2 + 𝜎2. 
Thus, in our design, the decision rule can equivalently be described as follows in terms of 
?̅?𝐿 and ?̅?𝑈:  
 If  ?̅?𝑛1 < ?̅?𝐿 , stop the trial at the end of the first stage for futility,  reject the 
alternative hypothesis and claim the treatment is not promising; 
 If  ?̅?𝑛1 > ?̅?𝑈, stop the trial at the end of the first stage for efficacy, reject the null 
hypothesis and claim the study therapy is promising; 
 Otherwise, if ?̅?𝐿 ≤ ?̅?𝑛1 ≤ ?̅?𝑈  continues to the second stage with additional 𝑛2 
patients.  
 
(4) 
  (5) 
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2.3.3  Frequentist Operating Characteristics 
For the above described futility design, the probability of failing to reject 𝐻0 with the 
true mean level 𝜇 is given by  
𝜑(𝜇, 𝜎, 𝑛1 , 𝑛2, ?̅?𝑛1 , ?̅?𝐿 , ?̅?𝐿
′) = 𝑃𝜇(?̅?𝑛1 ≤ ?̅?𝐿) + ∫ 𝑓𝜇(𝑥)𝑃𝜇(?̅?𝑛1+𝑛2 ≤ ?̅?𝐿
′)
∞
 ?̅?𝐿
𝑑𝑥
=   𝑃𝜇(?̅?𝑛1 ≤ ?̅?𝐿) + ∫ 𝑓𝜇(𝑥)𝑃𝜇(?̅?𝑛2 ≤
?̅?𝐿
′(𝑛1 + 𝑛2) − 𝑥𝑛1
𝑛2
)
∞
 ?̅?𝐿
𝑑𝑥 
=  𝛷(
?̅?𝐿 −  𝜇
𝜎/√𝑛1
)
+ ∫
1
√2𝜋𝜎2/𝑛1
exp (−
(𝑥 − 𝜇)2
2𝜎2
𝑛1
)𝛷(
?̅?𝐿
′(𝑛1 + 𝑛2) −  𝑥𝑛1
𝑛2
− 𝜇
𝜎/√𝑛2
)
∞
 ?̅?𝐿
𝑑𝑥 
In equation (6), 𝑓𝜇(𝑥) is the probability density function (PDF) of ?̅?𝑛1 when the true 
mean level of efficacy is 𝜇.  ?̅?𝐿 was derived from 𝑃𝐿 as described above. ?̅?𝐿
′  was defined 
as the low boundary for the sample mean to claim a positive trial from  𝑁𝑚𝑎𝑥 patients, 
which was obtained based on posterior probability. Although this is slightly different from 
Lee and Liu’s design, we obtain almost identical results if we assume the predictive 
probability of enrolling future patients is 0 when we reach 𝑁𝑚𝑎𝑥 by the end of second stage. 
Equation (6) consists two parts. The first part is the probability of stopping the trial at the 
end of the first stage due to futility, and second part is the probability of failing to reject 
the null at the end of the second stage.  Thus, the overall type I error (𝛼) and type II error 
rate (𝛽) can be expressed as  
𝛼 = 1 − 𝜑(𝜇0, 𝜎, 𝑛1 , 𝑛2 , ?̅?𝑛1 , ?̅?𝐿 , ?̅?𝐿
′)  (7) 
(8) 
(6) 
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𝛽 =  𝜑(𝜇1, 𝜎, 𝑛1 , 𝑛2 , ?̅?𝑛1 , ?̅?𝐿 , ?̅?𝐿
′) 
The probability of early termination, 𝑃𝐸𝑇(𝜇0), at the end of the first stage under the null 
hypothesis is   
𝑃𝐸𝑇(𝜇0) =  𝑃𝜇(?̅?𝑛1 ≤ ?̅?𝐿|𝐻0) 
The expected sample size under the null hypothesis 𝐸(𝑁|𝜇0) is  
𝐸(𝑁|𝜇0) =  𝑛1 + (1 − 𝑃𝐸𝑇(𝜇0)) ∗ 𝑛2 
 
2.3.4 Optimization Criteria 
Although our proposed two-stage PP design is based on Bayesian predictive 
probability framework, we wish to only consider designs that satisfy both type I and type 
II error rates constraints. Similar to those proposed by Simon [19], we use optimal design 
that minimizes the expected sample size, 𝐸(𝑁|𝜇0), under the null hypothesis, while 
minimax design that minimizes the maximum sample size.  
To find the optimal and minimax design, the following parameters should be pre-specified:  
 Maximum uninteresting mean and minimum interesting mean: 𝜇0 and  𝜇1 
 Likelihood variance: 𝜎2 
 Prior distribution for mean 𝜇:  𝑁(𝜃, 𝜏2) 
 Lower and upper boundaries of predictive probability: 𝑃𝐿 and 𝑃𝑈 
 Threshold posterior probability: 𝑃𝑇 
 Nominal type I and type II error rate constraint: 𝛼 and 𝛽 
(9) 
(10) 
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𝑃𝐿 , 𝑃𝑈 and 𝑃𝑇 should be between 0 and 1. When we want to stop the trial early 
only for futility, we chose 𝑃𝑈 = 1.0 not to allow early stopping for efficacy since there are 
situations when the treatment is beneficial for patients, there is little reason to stop the trial 
early. In addition, it will help gain more precision for the estimation of clinical endpoints 
of interest and provide more information for future large trials. 𝑃𝑇 is usually a large positive 
constant between 0 and 1, in this paper, we set the searching range for 𝑃𝑇 as [0.9 - 0.99].  
𝑃𝐿 is usually a small positive constant, which we set as [0.001 – 0.1] for the searching range 
in this study. How to choose 𝑃𝑇  and 𝑃𝐿  as well as their impact stopping rules will be 
discussed in Section 4. By searching over all possible values of in the range of 𝑃𝐿 and 𝑃𝑇, 
the goal is to identify the combinations of 𝑃𝐿 and 𝑃𝑇 to yield the desirable power within 
the constraint of the specified type I error rates.  The sample size from single-stage trial for 
continuous variables was used to derive the searching range for 𝑁𝑚𝑎𝑥 . Although a bit 
arbitrary, if we denote 𝑁 as the sample size required for the single-stage design, we used 
the range from 0.7𝑁 𝑡𝑜 1.7𝑁 to search for 𝑁𝑚𝑎𝑥. According to our simulation experiences, 
this range covers almost all the situations. Therefore, by varying 𝑛1 and 𝑁𝑚𝑎𝑥 from small 
to large, the design with the smallest expected sample size under the null hypothesis, that 
controls both type I and type II error rates at the nominal level, is defined the optimal design. 
Similarly, the design with the smallest 𝑁𝑚𝑎𝑥 is defined as the minimax design.  
 
2.4 Results 
Table 2.1 and Table 2.2 illustrate both optimal and minimax two-stage designs 
which only allows early termination for futility. The tabulated results vary by effect size 
(1, 0.8, 0.5 and 0.2). The effect size, also referred as to Cohen’s d, is defined as (𝜇1 −
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 𝜇0)/σ, where 𝜇0  and 𝜇1  are the average tumor size change under null and alternative 
hypothesis, respectively [68]. We chose 0.2, 0.5, 0.8 and 1 to cover the range of possibilities 
of small, medium and large effect sizes. We also provided other effect sizes from 0.1 to 0.9 
in the appendices (Table A3.1-3.4). Table 2.1 and Table 2.2 display 𝑃𝐿, 𝑃𝑇, total sample 
size from two-stages 𝑁𝑚𝑎𝑥, sample size for the first stage 𝑛1, the upper boundary of the 
reject region at the end of the first stage ?̅?𝐿 and the upper boundary of the reject region at 
the end of the second stage ?̅?𝐿
, . Following Lee and Liu’s definition, the reject region was 
the outcome space leading to the rejection of the new treatment/agent. The probability of 
early termination (PET), expected total sample size under the null hypothesis (𝐸𝑛) and 
actual type I and II error rates are also reported.  
In this scenario, we assume an average of 20% tumor size shrinkage after standard 
treatment or from historical control, and we wish to test if the new treatment or agent will 
improve the shrinkage to 30%. Thus, the null hypothesis is 𝐻0 : 𝜇 ≤ 20%  and the 
alternative hypothesis is 𝐻𝐴: 𝜇 ≥ 30%, where 𝜇0 = 20 and 𝜇1 = 30. Positive values of the 
parameter favor the new drug efficacy, whereas negative values represent the disease 
progression. We chose various 𝜎 (10, 12.5, 20 and 50) to compare the sample size for 
different effect sizes, where in practice,  𝜎 should be obtained from historical trials or 
estimated from standard treatment. We set ESS =   
𝜎2
𝜏2
= 1 and 𝜃 = 𝜇0 = 20. As described 
above, the searching range for 𝑁𝑚𝑎𝑥 was obtained from a single-stage trial with continuous 
endpoints. A grid search was performed through the space of 𝑃𝐿 [0.001 – 0.1] and 𝑃𝑇[0.9 
– 0.99] to enumerate all the combinations that meet pre-specified type I and type II error 
constraints.  
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For instance, in Table 2.1, when 𝜎 = 20 with effect size 0.5, type I and type II error 
rate constraints are 0.05 and 0.2, a grid search of 𝑃𝐿 and 𝑃𝑇 was performed for each 𝑁𝑚𝑎𝑥 
between 8 and 46. It turns out that the design with 11 patients in the first stage and 26 
patients in total is the optimal design, which has the smallest expected sample under the 
null hypothesis. 𝑃𝐿 and 𝑃𝑇 are determined to be 0.1 and 0.945, respectively. The trial will 
be stopped, and the new drug is considered not promising for further study when the 
average tumor size shrinkage from the first 11 patients is less than 20.69%. If the observed 
value of the mean of tumor size shrinkage from the first 11 patients is greater than 20.69%, 
the trial should continue to the second stage and enroll an additional 15 patients. The 
expected total sample size is 17.8, and the probability of early termination is 0.55 when the 
true mean tumor size change is 20%. Alternatively, the minimax design requires 25 patients 
in total with 18 patients in the first stage (Table 2.2). In fact, the minimax design usually 
gives a smaller total sample size but larger 𝑛1, ?̅?𝑛1, 𝐸𝑛 and PET. This trend is consistent 
with both Simon’s and Hsiao’s designs [19, 56]. As expected, the total sample size required 
decreases as effect size increases.   
Table 2.3 and 2.4 display the optimal designs and minimax designs, which allow 
early termination due to either futility or efficacy. In both designs, we use 𝑃𝑈 = 0.95 to 
make the efficacy stopping decision. Using the same example, when 𝜎 = 20 with effect 
size 0.5, type I and type II error rate constraints are 0.05 and 0.2, the optimal design yields 
the same total sample 26 with 12 patients required for the first stage (Table 2.3). The trial 
will be stopped and the new drug is considered not promising for further study when the 
average tumor size shrinkage from the first 11 patients is less than 21.20%. If the observed 
value of the mean of tumor size shrinkage from the first 11 patients is greater than 33.86%, 
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the trial should be stopped early for efficacy. Otherwise, an additional 14 patients will be 
enrolled for the 2nd stage. The corresponding operating characteristics are very similar to 
the futility design. That is because we choose  𝑃𝑈 = 0.95, which is close to 𝑃𝑈 = 1. As the 
𝑃𝑈 decreases, the total sample size increases. 
2.4.1 Roles of priors 
As mentioned above, ESS can be interpreted as the amount of information 
contained in the prior. In the case of normal distribution, ESS is 𝜎2/𝜏2. To investigate the 
roles of normal conjugate priors in this proposed design, we considered two groups of 
priors: “pessimistic” priors that set the mean of normal prior equal the maximum 
uninteresting mean ( 𝜃 =  𝜇0 ) under the null hypothesis and the other group is for 
“optimistic” priors that set the prior mean equal to the minimum mean of interest (𝜃 =  𝜇1) 
under the alternative hypothesis.  For each group, we assessed two priors, one “weaker” 
prior with ESS = 1 and one “stronger” with ESS = 5. For purposes of illustration, we still 
use effect size = 0.5 as an example with 𝜇0 = 20  and 𝜇1 = 30.Thus, four priors were used 
as follows: 
 Weak pessimistic prior: 𝑁(20, 202), ESS = 𝜎2/𝜏2  =  1 
 Strong pessimistic prior: 𝑁(20, 8.942), ESS = 𝜎2/𝜏2 =  5 
 Weak optimistic prior: 𝑁(30, 202), ESS = 𝜎2/𝜏2  =  1 
 Strong optimistic prior: 𝑁(30, 8.942), ESS =𝜎2/𝜏2 =  5 
The numeric results of both optimal and minimax design are shown in Table 2.5 
and Table 2.6. For the four optimal designs under different priors (Table 2.5), the total 
sample size is the same as 26. Under two stronger priors 𝑁(20, 8.942) and N(30, 8.942), 
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the strong optimistic prior N(30, 8.942) results in a larger expected sample size of 18.97 
under the null hypothesis, compared to 17.32 from the strong pessimistic prior  
𝑁(20, 8.942). It is intuitive since the trial is less likely to be terminated early due to futility 
under the null hypothesis if the optimistic prior belief is true (PET = 0.58 for prior  
𝑁(20, 8.942) vs. PET = 0.54 for prior 𝑁(30, 8.942)). Under two weaker priors 𝑁(20, 202) 
and 𝑁(30, 202), the PET is the same but the optimistic prior also leads to a larger expected 
sample size of (18.25 vs. 17.81) under the null hypothesis. When comparing the minimax 
design (Table 2.6), all the four priors resulted in the sample maximum sample size (𝑁 =
25). The two weaker priors need a larger sample size from the first stage n1  than the 
stronger priors.  
2.4.2 Case Study 
In this section, we refer to the case study illustrated in Wason et al. [5]. In this case 
study, the primary endpoint was the maximum shrinkage in total lesion diameter and was 
previously classified as a binary variable according to RECIST criteria. Thus, the trial was 
previously designed using a Simon’s two-stage design. In their proposed two-stage design, 
Wason et al. demonstrated that using continuous endpoints, instead of classified binary 
endpoints, there was about 50% reduction in both expected and maximum sample size. 
According to their notation, the mean treatment efficacy (true tumor shrinkage) was 
denoted by 𝛿. The hypothesis testing framework was 𝐻0: 𝜇 ≤ 𝜇0 vs. 𝐻1: 𝜇 ≥ 𝜇1, where 
𝜇0 = −7.6 and 𝜇1 =  11.1, with known 𝜎 = 36.4. Under this setup, Wason’s optimal 
continuous design yielded a first and second stage sample size of 15 and 24, respectively, 
which compared with Simon’s two-stage optimal design (30 patients are required for the 
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first stage and 52 patients were required for the second stage), led to around 50% reduction 
in the sample size for both stages.  
We apply our Bayesian PP design for this trial scenario. In particular, 𝜇0 = −7.6, 
𝜇1 =  11.1, and 𝜎 = 36.4. We chose the prior as 𝑁(−7.6,  36.4
2) and set the same type I 
and II error rates as 0.05 and 0.1, respectively. The searching range for 𝑃𝐿  is [0.001 - 0.1] 
and for 𝑃𝑇 is [0.9 - 0.99]. These values result in the optimal continuous design having the 
first stage sample size of 14 and total sample size of 34. The expected sample size under 
the null is 23.4. The cut-off value for tumor size change from the first 14 patients is -6.86, 
with 𝑃𝑇 = 0.945 and 𝑃𝐿 = 0.099 (Table 2.7). The result is very similar to Wason et al., but 
requires a slightly smaller sample size in the second stage.  
 
2.5 Discussion  
In practice, RECIST criteria is commonly applied to categorize the tumor shrinkage 
into complete response, partial response, progressive disease, and stable disease. Response 
rate, which is the combination of complete and partial response, with at least a 30% 
decrease in the sum of the longest diameter of the target lesions, is usually used as a 
secondary endpoint in most of the cancer trials. However, as shown in the previous studies, 
this dichotomization not only lead to loss of statistical efficiency, but greatly increases the 
required sample size [5, 54, 56].  
In this proposed design, we extended Lee and Liu’s predictive probability approach 
into a two-stage setting for continuous endpoint. Similar as Wason et al., we obtained 
decreased sample size when treating tumor shrinkage as continuous variable. The design 
parameters  𝑃𝐿 , 𝑃𝑈 , and 𝑃𝑇  plays an important role in searching for the optimal and 
 31 
 
minimax designs. As mentioned above, we chose 𝑃𝑈 = 1 to only allow for early futility 
stopping.  Regarding the choice of 𝑃𝐿, 𝑃𝑈, and 𝑃𝑇, no definitive and clear guidelines have 
been proposed for the binary endpoints. We adopted similar strategy as described in Lee 
and Liu’s paper and Dong et al’s research [37, 39].  We set the range of 𝑃𝑇 for searching 
as [0.9 - 0.99]. 𝑃𝑇 can be viewed as a reasonable degree of certainty, which could be 0.9, 
0.95 and 0.99, according to FDA guidelines for the use Bayesian statistics in medical 
device clinical trials [39, 69]. The lower boundary for 𝜃𝑇 can be reduced to 0.8, as Lee and 
Liu did in their binary PP design.  In general, as 𝑃𝑇  increases, it is harder to reject 𝐻0. 
Therefore, the higher 𝜃𝑇 is, the lower power and actual type I error it will be. There is no 
general guideline for choosing 𝑃𝐿. Lee and Liu set the search range for 𝑃𝐿 as [0.001 - 0.1], 
while Dong et al. used values up to 𝑃𝐿 = 0.5 [39]. We applied the same rule as Lee and Liu, 
since a smaller value of 𝑃𝐿 indicates that it is very unlikely the mean tumor size change 
will be larger than 𝜇0 given current information, which turns into harder rejection of 𝐻0 
due to futility as well as increased power and type I error rates.  
We also assessed the operating characteristics for the optimal designs based on the 
posterior approach. Our simulation results have shown that a two-stage design based on 
the posterior approach is more conservative, and always yields a little bit larger total sample 
size 𝑁𝑚𝑎𝑥 and larger ?̅?𝑛1 (data not shown). For instance, if we use posterior probability 
approach for the case study, the ?̅?𝑛1 is -2.59, and we need 39 patients in total with 15 
patients for the first stage, which happened to be the same as Wason’s design. However, 
as mentioned in Lee and Liu’ s paper, predictive probability approach has the advantages 
that it mimics the decision making process in reality and more intuitive [37].  
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We explored and evaluated the roles of priors for this PP design. In practice, prior 
information is usually obtained from standard treatment or historical control. ESS 
represents the weight we place on the prior information known before the trial. In this paper, 
we began with ESS = 1, assuming a weak prior. The total sample size remains robust with 
stronger priors (ESS = 5) for both optimal and minimax designs. The comparison is 
illustrative but not conclusive. Based on our simulation, ESS should not exceed 1/3 of the 
total sample size. Future work on the exploration of other non-conjugated priors is needed.  
There are several limitations to this current design that we plan to address in future 
work. Firstly, in this proposed design, we assume the standard deviation 𝜎 is known in line 
with Wason’s design. It is reasonable since in practice, this value could be obtained from 
previous trials or preclinical studies. However, when there is little prior information 
available, especially for novel drugs or biomarkers, unknown variance may be explored in 
the future. Secondly, this design currently accommodates only one interim look for futility, 
and we plan to eventually incorporate continuously monitoring for both futility and 
superiority. Further, priors are important in Bayesian clinical trial designs. It is always 
challenging and controversial to choose a suitable prior on the parameter of interest. In this 
paper, we only chose the conjugate priors for the mean, assuming variance is known, and 
explored briefly on the roles of pessimistic and optimistic priors. There could be clinical 
situations where the prior does not follow a normal distribution, and thus the resulting 
posterior does not have a closed form.  More exploration is needed in this regard. 
Overall, we have shown a two-stage design using predictive probability for 
continuous endpoints. We have demonstrated similar sample size reduction as Wason’s 
design. We developed R programs to perform this proposed design and the code will be 
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available in an upcoming R package, but these functions are available upon request. As 
research rapidly moves to incorporate more immunotherapies and targeted therapies, these 
designs will accommodate new types of outcomes while allowing for flexible stopping 
rules for futility and/or efficacy to continue optimizing trial resources and prioritizing 
agents with compelling early phase data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
 
Figure 2.1 Proposed two-stage PP design for continuous endpoints. 
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Table 2.1 Operating characteristics of optimal design for continuous endpoints with early termination for futility. For both designs 
below,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with type I and type II 
error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
Optimal Design 
Effect size σ 𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝐿
′ PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
1.0 10 0.945 0.100 7 3 21.49 26.46 0.60 4.59 0.040 0.199 
0.937 0.100 9 4 20.98 25.38 0.58 6.11 0.050 0.099 
0.8 12.5 0.938 0.100 10 5 21.67 26.38 0.62 6.91 0.050 0.199 
0.941 0.096 14 6 20.63 25.41 0.55 9.60 0.050 0.100 
0.5 20 0.945 0.100 26 11 20.69 26.39 0.55 17.81 0.048 0.199 
0.945 0.100 36 15 20.46 25.40 0.54 24.76 0.049 0.099 
0.2 50 0.947 0.100 160 71 20.77 26.41 0.55 110.93 0.049 0.200 
0.947 0.100 223 96 20.51 25.42 0.54 154.48 0.050 0.100 
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Table 2.2 Operating characteristics of minimax design for continuous endpoints with early termination for futility. For both designs 
below,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with type I and type II 
error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
Minimax Design 
Effect 
size 
σ 𝑃𝑇  𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝐿
′ PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
1.0 10 0.945 0.100 7 3 21.49 26.46 0.60 4.59 0.040 0.199 
0.937 0.100 9 4 20.98 25.38 0.58 6.11 0.050 0.099 
0.8 12.5 0.938 0.100 10 5 21.67 26.38 0.62 6.91 0.050 0.199 
0.941 0.096 14 6 20.63 25.41 0.55 9.60 0.050 0.100 
0.5 20 0.945 0.080 25 18 23.09 26.52 0.74 19.79 0.050 0.200 
0.946 0.069 35 18 20.72 25.51 0.56 25.47 0.050 0.100 
0.2 50 0.949 0.080 155 149 25.46 26.59 0.91 149.55 0.050 0.200 
0.948 0.081 217 146 22.23 25.53 0.70 166.95 0.050 0.100 
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Table 2.3 Operating characteristics of optimal design for continuous endpoints with early termination for efficacy. For both designs 
below,  𝑃𝑈 = 0.95,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with type I 
and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
Optimal Design 
Effect size σ 𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝑈 PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
1.0 10 0.946 0.100 7 3 21.54 35.33 0.61 4.57 0.041 0.200 
0.940 0.088 9 4 20.80 32.65 0.57 6.15 0.050 0.100 
0.8 12.5 0.942 0.073 10 5 21.11 33.90 0.59 7.08 0.049 0.200 
0.944 0.093 14 7 21.30 31.54 0.62 9.69 0.050 0.100 
0.5 20 0.947 0.100 26 12 21.20 33.86 0.59 17.74 0.050 0.199 
0.948 0.100 36 18 21.31 31.20 0.62 24.87 0.050 0.099 
0.2 50 0.951 0.100 163 72 20.89 33.82 0.57 111.20 0.050 0.200 
0.951 0.100 226 103 20.87 31.54 0.58 154.66 0.05 0.100 
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Table 2.4 Operating characteristics of minimax design for continuous endpoints with early termination for efficacy. For both designs 
below,  𝑃𝑈 = 0.95,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ = σ. The first row for each effect size is with type I 
and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
Minimax Design 
Effect size σ 𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝑈 PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
1.0 10 0.936 0.100 7 3 21.13 34.93 0.58 4.67 0.050 0.176 
0.942 0.072 9 4 20.44 32.72 0.54 6.30 0.048 0.100 
0.8 12.5 0.941 0.100 10 6 22.61 32.34 0.70 7.19 0.050 0.200 
0.944 0.093 14 7 21.30 31.54 0.62 9.69 0.050 0.100 
0.5 20 0.948 0.030 25 17 21.55 31.31 0.64 19.92 0.050 0.200 
0.949 0.052 35 20 20.91 30.59 0.59 26.15 0.050 0.100 
0.2 50 0.950 0.030 155 140 24.16 28.80 0.86 142.16 0.050 0.200 
0.951 0.003 215 172 20.97 25.66 0.61 188.60 0.050 0.100 
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Table 2.5 Operating characteristics of optimal futility designs with different priors. (Design parameter: μ0 = 20, μ1 = 30, α =  0.05,
β = 0.2, σ = 20)  
Prior 
N(𝜃, 𝜏2)
𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝐿
′ PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
 𝑁(20, 202) 0.945 0.100 26 11 20.69 26.39 0.55 17.81 0.048 0.199 
𝑁(20, 8.942) 0.930 0.099 26 11 21.20 26.32 0.58 17.32 0.049 0.200 
𝑁(30, 202) 0.957 0.100 26 12 20.78 26.48 0.55 18.25 0.047 0.200 
𝑁(30, 8.942) 0.976 0.100 26 13 20.57 26.55 0.54 18.97 0.046 0.199 
Table 2.6 Operating characteristics of minimax futility designs with different priors. (Design parameter: μ0 = 20, μ1 = 30, σ =
20, α =  0.05, β = 0.2)  
Prior 
N(𝜃, 𝜏2)
𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿 ?̅?𝐿
′ PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
  𝑁(20, 202) 0.945 0.081 25 18 23.10 26.52 0.74 19.79 0.050 0.200 
𝑁(20, 8.942) 0.932 0.039 25 13 20.26 26.53 0.52 18.77 0.050 0.200 
𝑁(30, 202) 0.955 0.079 25 16 22.16 26.52 0.67 19.00 0.050 0.200 
𝑁(30, 8.942) 0.975 0.047 25 15 20.44 26.59 0.53 19.66 0.049 0.200 
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Table 2.7 Operating characteristics of optimal design and minimax design for case study. The searching range for 𝑃𝑇 is [0.9 – 0.99] and 
𝑃𝐿 is [0.001 – 0.1]. μ0 = −7.6, μ1 =  11.1, σ = 36.4 . θ = μ0 = −7.6, τ =  σ = 36.4 and (α, β) = (0.05, 0.1).  
 
 𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿  ?̅?𝐿
′  PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
Optimal Design 0.945 0.099 34 14 -6.86 2.52 0.53 23.40 0.049 0.100 
Minimax Design 0.943 0.083 33 18 -5.30 2.56 0.61 23.91 0.049 0.098 
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CHAPTER THREE 
A Multi-Stage Predictive Probability Interim Design for Phase II Clinical Trials 
with Continuous Endpoints 
3.1 Abstract 
Numerous phase II cancer clinical trial designs are based on binary response rate 
outcomes. The loss of information is particularly inefficient due to the dichotomization of 
tumor shrinkage according to RECIST criteria. In this paper, we extended Lee and Liu’s 
probability predictive design for binary outcomes into a single-arm multi-stage setting for 
continuous endpoints, such as continuous tumor shrinkage in cancer trials or any other 
short-term response endpoints. We present the numeric simulation outputs for minimax 
designs with different prior distributions, while maintaining robust results. This predictive 
probability design is flexible due to its Bayesian properties. It keeps updating the 
information during the trial as the patients are continuously enrolled. In the meanwhile, it 
also controls the frequentist type I and type II error rates. We also developed R programs 
to assist with the study design. 
Keywords: Multi-stage design; Predictive probability; Interim strategy; Continuous 
endpoints 
 
3.2 Introduction 
Phase II clinical trials aim to screen out those ineffective treatment or therapies, 
and identify those effective ones to move forward to larger confirmatory randomized phase 
III trials. As a result, phase II trials tend to have shorter study periods, smaller sample sizes, 
and endpoints that aim to be predictive to the definitive phase III trials. In cancer phase II 
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trials, a commonly used endpoint is objective response rate, which is dichotomized from 
continuous tumor shrinkage according to RECIST [1]. 
Many designs have been proposed to target potential promising new therapies for 
phase II trials, among which at least one interim look is usually incorporated to utilize the 
information from the interim data that has already been obtained. In the setting of single 
treatment regimen or one-arm design, for the purpose of evaluating the efficacy, Gehan’s 
design and Simon’s two-stage design as well as Fleming’s two-stage design are still the 
most widely used two-stage designs in practice [18-19,61].In some scenarios,three-stage 
design and multi-stage design are preferred to two-stage designs, since they are usually 
more efficient when compared to the two-stage design, especially when the effect size is 
small, and total sample size required is large. A multi-stage design is more efficient to 
terminate the trial early if the new therapy is not effective [20, 70]. Chen extended Simon’s 
two-stage design into a three-stage design and claimed that the average sample size 
reduction from two-stage to three-stage is about 10% when the null hypothesis is true [20]. 
Fleming proposed a multiple testing procedure for one-sample design to allow for early 
termination while maintaining the statistical properties. In the randomized setting, group 
sequential designs have been widely employed, with Pocock’s design and O’Brien and 
Fleming’s design as two commonly used group-sequential options[62, 63]. 
On the other hand, Bayesian clinical trial designs have gained popularity due to 
their flexibility to include sequential stoppings when compared with their frequentist 
counterparts. Thall and Simon introduced a class of phase II Bayesian clinical trial designs 
[28].  Tan and Machin proposed a two-stage design based on the posterior distribution [29]. 
Sambucini extended it into a two-stage design based on predictive distribution [30, 31]. 
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Wang et al. and Dong et al. developed two Bayesian single-arm two-stage designs 
incorporating both frequentist and Bayesian error rates [34, 39]. In particular, Lee and Liu 
proposed a predictive probability design for single-arm trial with binary outcome to 
monitor the trial continuously[37].  
Although this binary endpoint is intuitive to understand and widely adopted in 
practice, loss of information from the dichotomization cannot be avoided. In addition, with 
the development of molecular targeted therapies and immunotherapies, drugs can be still 
active and patients can benefit from those “minor response” or “mixed response”, even 
though drugs do not lead to high-levels of tumor regression and do not meet the criteria of 
response rates [6, 71, 72]. Therefore, using continuous tumor shrinkage instead of the 
binary response rate has been proposed in previous studies [5, 53-56, 58]. However, these 
designs can be extended to any continuous outcomes, for example, biomarker assessment 
over time. In this paper, we extended Lee and Liu’s predictive probability design into a 
single-arm setting with continuous outcome. This manuscript is organized into the 
following sections. Section 3.3 details our proposed design and trial decision rules. Section 
3.4 displayed the numeric results from the simulation and case study. Section 3.5 is to 
discuss the strengths, limitations and future directions of current design.   
 
3.3. Methods 
3.3.1 Notation and Proposed Design 
In this paper, we extend Lee and Liu’s 𝑃𝑃 design into a multi-stage design for 
continuous endpoints. The hypothesis testing framework is as follows: 
𝐻0: 𝜇 ≤  𝜇0  vs. 𝐻1: 𝜇 ≥  𝜇1 
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where 𝜇0  represents the maximum efficacy from the standard treatment or historical 
control, and  𝜇1 represents a target efficacy threshold from the treatment or therapy being 
studied. This extended design also meets both pre-specified Type I and Type II error rate 
constraints.  
For illustration purposes, we  define “tumor size change” as the percentage decrease 
in the sum of the longest diameter of the target lesions compared to baseline for each patient, 
with positive values denoting tumor shrinkage [73]. We assume the average tumor 
shrinkage, 𝑋, follows a normal distribution 𝑁( 𝜇, 𝜎2),  with mean 𝜇 and known variance 
𝜎2. We assume a normal conjugate prior distribution for 𝜇, 𝑁(𝜃, 𝜏2), which represents the 
investigator’s previous knowledge of the tumor size change from standard treatment or 
historical control. We use effective sample size for the prior (ESS),  
𝜎2
𝜏2
 for the normal case, 
to assign the amount of information for the prior [67, 73]. For the purpose of simulation, 
we set ESS = 1, assuming very little knowledge is known before the trial starts. We also 
compare the effect of different ESS specifications in the results section.  
Here, we consider a single-arm 𝐾 -stage design, where  𝐾 ≤  𝑁𝑚𝑎𝑥. At the end of 
𝑖𝑡ℎ stage, the number of patients enrolled in total is denoted as 𝑛𝑖, where 𝑖 = 1, 2, … , 𝐾.  
We denote ?̅?𝑛𝑖 as the average tumor shrinkage for the current 𝑛𝑖 patients. Therefore, given 
the information from these current 𝑛𝑖 patients, the posterior distribution of the mean tumor 
shrinkage 𝜇 follows a normal distribution, with mean  
𝜎2𝜃
𝑛𝑖𝜏
2+𝜎2
+ 
𝑛𝑖𝜏
2
𝑛𝑖𝜏
2+𝜎2
?̅?𝑛𝑖 and variance 
𝜏2𝜎2
𝑛𝑖𝜏
2+𝜎2
. Thus, the average tumor shrinkage from the future 𝑚𝑖  patients, where 𝑚𝑖 =
 𝑁𝑚𝑎𝑥 − 𝑛𝑖, follows a normal distribution with mean 𝜇𝑝
∗  and 𝜎𝑝
∗2, where   
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𝜇𝑝
∗ = 
𝜎2𝜃
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
+ 
𝑛𝑖𝜏
2
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
?̅?𝑛𝑖 +
𝑚𝑖𝜏
2?̅?𝑚𝑖
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
 
𝜎𝑝
∗2 = 
𝜏2𝜎2
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
 
We define 𝐵𝑖 = 𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) to measure the probability that the mean tumor 
shrinkage is larger than 𝜇0, given the mean tumor size change in current 𝑛𝑖 patients and 
future 𝑚𝑖 patients. We can conclude the treatment is efficacious when 𝐵𝑖 > 𝑃𝑇, where 𝑃𝑇 
is the posterior critical value at each stage and is usually assumed to be greater than 0.8. 
𝐵𝑖 =  𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) = 1 − 𝑃𝑟𝑜𝑏(𝜇∗ ≤ 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) 
= 1 −  𝛷 (
𝜇0− 𝜇𝑝
∗
𝜎𝑝
∗ ) > 𝑃𝑇  
where 𝛷 (.) represents the cumulative density function (CDF) of the standard normal 
distribution. The above inequality (1) can be derived into an inequality of ?̅?𝑚𝑖 regarding 
𝑃𝑇.  
?̅?𝑚𝑖 >
((𝑛𝑖+𝑚𝑖)𝜏
2+𝜎2)(𝜇0− 𝜎𝑝
∗𝛷−1(1−𝑃𝑇))− 𝜎
2𝜃−𝜏2𝑛𝑖?̅?𝑛𝑖
𝑚𝑖𝜏
2 = 𝛿  
The posterior predictive distribution of tumor size change from the future 𝑚 patients also 
follows a normal distribution 𝑁(𝜇𝑝, 𝜎𝑝
2) , with  𝜇𝑝 = 
𝜎2𝜃
𝑛𝑖𝜏
2+𝜎2
+ 
𝑛𝑖𝜏
2
𝑛𝑖𝜏
2+𝜎2
?̅?𝑛𝑖  and 𝜎𝑝
2 =
 
𝜎2
𝑚𝑖
+ 
𝜏2𝜎2
𝑛𝑖𝜏
2+𝜎2
.  
Based on all the information above, we can then define the predictive probability (𝑃𝑃)  
Predictive probability (𝑃𝑃) = 𝑃𝑟𝑜𝑏(?̅?𝑚𝑖 > 𝛿|?̅?𝑛𝑖) 
= 1 − 𝑃𝑟𝑜𝑏(?̅?𝑚𝑖 ≤ 𝛿|?̅?𝑛𝑖) = 1 −  𝛷 (
𝛿 − 𝜇𝑝 
𝜎𝑝
)  
(1) 
(2) 
(3) 
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A high 𝑃𝑃 means that given current data, the treatment is likely to be efficacious by the 
end of the study; whereas a low 𝑃𝑃 suggests that the treatment may not have sufficient 
activity. Therefore, we use 𝑃𝑃 to make the decision during the interims in the trial.  
3.3.2 Trial Decision Rules 
For this proposed design, we have the flexibility to stop the trial early either due to 
futility and superiority. We use similar decision rules as those described in Lee and Liu’s 
𝑃𝑃 design and our two-stage design [37, 73]. For a K-stage design (𝐾 < 𝑁𝑚𝑎𝑥), we denote 
𝑃𝑃𝑖 as the predictive probability at the end of 𝑖
𝑡ℎ  stage (𝑖 ≤ 𝐾). We also denote 𝑃𝐿 and 𝑃𝑈 
as the lower and upper boundaries for 𝑃𝑃𝑖, assuming 𝑃𝐿 and 𝑃𝑈 are constant for each stage. 
𝑃𝐿 and 𝑃𝑈   should be both between 0 and 1, where 𝑃𝐿 is usually a small positive number 
less than 0.1 and 𝑃𝑈 is usually a large number greater than 0.9.  By comparing 𝑃𝑃𝑖 with 𝑃𝐿 
and 𝑃𝑈 and solving for ?̅?𝑛𝑖, we can obtain ?̅?𝐿𝑖 and ?̅?𝑈𝑖, which are defined as the lower and 
upper bounds for the sample mean from current 𝑛𝑖   patients. Therefore, for a 𝐾-stage 
design, the decision rule can be described in terms of ?̅?𝐿𝑖 and ?̅?𝑈𝑖 at each stage:  
 If  ?̅?𝑛𝑖 < ?̅?𝐿𝑖, stop the trial for futility and reject the alternative hypothesis; 
 If  ?̅?𝑛𝑖 > ?̅?𝑈𝑖, stop the trial for efficacy and reject the null hypothesis; 
 Otherwise, if ?̅?𝐿𝑖 ≤ ?̅?𝑛𝑖 ≤ ?̅?𝑈𝑖, continue to the next stage.  
3.3.3 Frequentist Operating Characteristics 
As we want our design to meet both pre-specified type I and type II error rate 
constraints, we need to calculate the probability of rejecting the null hypothesis at each 
stage. Therefore, for the design described above, we obtain the average tumor shrinkage 
from the cumulative sample size of the patients at the end of each stage 𝑖, denoted as ?̅?𝑛𝑖, 
where ?̅?𝑛𝑖  follows a normal distribution with mean 𝜇  and variance 𝜎
2/𝑛𝑖 . If we 
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standardize ?̅?𝑛𝑖 and transform it into a test statistics, Z𝑛𝑖 = (?̅?𝑛𝑖 − 𝜇0)/(√𝜎
2/𝑛𝑖), for a 
given design that continues to the end, the vector of Z = (Z𝑛1 , Z𝑛2 , … , Z𝑛𝐾) is multivariate 
normally distributed with the mean (𝜇 − 𝜇0)/(√𝜎2/𝑛𝑖)  and variance 1. The covariance 
between Z𝑛𝑖  and Z𝑛𝑗  is √
𝑛𝑖
𝑛𝑗
 for 𝑛𝑖 < 𝑛𝑗  [74]. Therefore, the vector of the ?̅?  = 
(?̅?𝑛1 , ?̅?𝑛2 , … , ?̅?𝑛𝐾), is assumed to follow a multivariate normal distribution, with mean 𝜇 
and variance 
𝜎2
𝑛𝑖
(𝑖 = 1,2, . . , 𝐾). The covariance between ?̅?𝑛𝑖  and ?̅?𝑛𝑗 , with 𝑛𝑖 < 𝑛𝑗 , is 
𝜎2/ 𝑛𝑗. The probability of rejecting 𝐻0 with the true mean 𝜇 at each stage can be expressed 
as:  
Pr(𝑟𝑒𝑗𝑒𝑐𝑡 𝑡ℎ𝑒 𝐻0 at stage 𝑖 ) 
                                        = ∫ …
?̅?𝑈1
?̅?𝐿1
∫ ∫ 𝑓?̅?(?̅?𝑛1 , ?̅?𝑛2 , … , ?̅?𝑛𝑖|𝜇)
∞
?̅?𝑈𝑖
?̅?𝑈𝑖−1
?̅?𝐿𝑖−1
 𝑑?̅?𝑛𝑖
𝑑?̅?𝑛𝑖−1
…𝑑?̅?𝑛1 ,  
where 𝑓?̅? is the probability density function (pdf) of the multivariate normal distribution 
with mean vector and covariance matrix as previously described. ?̅?𝑈𝑖  and ?̅?𝐿𝑖  are 
boundaries  obtained from predictive probabilities 𝑃𝐿 and 𝑃𝑈 at each stage 𝑖. When the trial 
continues to the last stage 𝐾, ?̅?𝑈𝐾 and ?̅?𝐿𝐾 are obtained from the posterior probability. In 
the two-stage paper, we compare the results with the scenario, in which we assume the 
predictive probability of enrolling future patients is 0 when we reach 𝑁𝑚𝑎𝑥. It has been 
shown to be very similar in the two scenarios. Therefore, the type I error and power can be 
calculated by summing up the probability of rejecting the null hypothesis at each stage 
when the null and alternative hypothesis is true, respectively [55]. 
To evaluate the multidimensional integral in the equation above, wo strategies are 
applied. One directly integrates the multivariate normal density [75, 76]. Computation time 
(4) 
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for the direct numeric integration is much less when the design only contains 3 or fewer 
stages. Thus, we utilize a published R package, which contains a function to perform a 
Monte Carlo algorithm and evaluate the integrand for 4 or more desired stages, as the 
computation time reduces significantly [77]. The actual type I error can be calculated by 
summing up (4) from each stage 𝑖 when 𝜇 =  𝜇0, with its value under 𝜇 =  𝜇1 yielding the 
power. One limitation for the current R package we utilized to evaluate the 
multidimensional integral is that only up to 40 stages is allowed due to their algorithm used 
in the package. 
3.3.4 Optimization Criteria 
This current proposed design is based on predictive probability and, similar to the 
two-stage design, we wish our design to meet both pre-specified type I and type II error 
rates constraints. In general, 𝑃𝐿 is usually chosen as a very small number, eg. less than or 
equal to 0.1, while 𝑃𝑈 is usually chosen as a very large number, eg. greater than or equal 
to 0.9. Both Lee and Liu’s study and Dong et al. have suggested guidelines for the searching 
range of these parameter [37, 39]. In this design, we restrict 𝑃𝐿  as 0.1 and 𝑃𝑈  as 0.95, 
instead of searching 𝑃𝐿 and 𝑃𝑈 in a range, across all the stages in current manuscript, due 
to the grid search strategy. As the number of parameters increases, the computation time 
increases quickly. On the other hand, we set the searching range for 𝑃𝑇 to be [0.90 - 0.99]. 
In the two-stage paper, we already discussed how to choose 𝑃𝑇  and 𝑃𝐿  and their impact 
on stopping rules [73]. By searching through the range of 𝑃𝑇, we can identify the design 
that will yield desirable power within the constraint of the specified type I error rates. To 
determine the searching range for 𝑁𝑚𝑎𝑥, we use the 0.8 to 1.5 times of the sample size from 
the single-stage design for continuous variables as the searching boundaries. In this paper, 
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we only consider the minimax design here, which is to minimize the maximum sample size 
[19]. If there are more than one design with the same total sample size, we select the design 
with largest power.  
To find the minimax design, the following parameters must be pre-specified:  
 The number of stages in total 𝐾 
 The proportions of patients enrolled at each interim look  
 Maximum uninteresting mean and minimum interesting mean: 𝜇0 and  𝜇1 
 Likelihood variance: 𝜎2 
 Prior distribution for mean 𝜇:  𝑁(𝜃, 𝜏2) 
 Lower and upper boundaries of predictive probability: 𝑃𝐿 and 𝑃𝑈 
 Threshold posterior probability: 𝑃𝑇 
 Nominal type I and type II error rate constraints: 𝛼 and 𝛽 
 
3.4 Results 
We present the simulation results for 3-stage to 10-stage design for this proposed 
minimax design in Table 3.1 and Table A3.1. We assume the sample size at each stage is 
approximately equally spaced. We also tested effect sizes of 1, 0.8, 0.5 and 0.2 (also 
referred as Cohen’s d), representing the ranges of large, medium and small effect sizes. We 
assume the prior mean 𝜃 equals to the likelihood mean 𝜇 and we set the ESS as 1, assuming 
very little information is known before the trial starts. Table 3.1 shows the results satisfying 
the pre-specified type I error rate of 0.05 and type II error rate of 0.2, while Table A3.1 
shows the results meeting the pre-specified type I error rate of 0.05 and type II error of 0.1.  
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In the presented simulation scenario, we assume an average of 20% tumor size 
shrinkage after standard treatment or historical control. Thus, the null hypothesis is 𝐻0 ≤
20%. We expect our new therapy to improve this tumor shrinkage to at least 30%. Thus, 
the alternative hypothesis is 𝐻1 ≥ 30%. Several observations were made according to the 
simulation results. Firstly, we initially search 0.7 – 1.7 times the sample size from one-
stage single-arm design for 𝑁𝑚𝑎𝑥 . It covers most of the situations according to our 
simulation experiences. However, if there were no combinations of the parameters that 
meet both type I and type II error constraints within this searching range, we need to extend 
the searching range for 𝑁𝑚𝑎𝑥. Secondly, as the number of stages increases, with the same 
effect size, the number of smallest sample size required slightly increases. From 3-stage 
design to 10-stage design, the total sample size increased by over 20%. This increment is 
even higher when type II error rate constraint is 0.1. Further, all the 𝑃𝑇 were determined to 
be in the middle of the searching range [0.9 − 0.99]. From our experience, as 𝑃𝑇 increases, 
the type I error rates decrease while the type II error rates increase (data not shown).  
3.4.1 Roles of priors 
Similar to our two-stage paper, we explored both pessimistic and optimistic priors and 
assessed their effect on the design operating characteristics. The four priors are listed below: 
 Weak pessimistic prior: 𝑁(20, 202), ESS = 𝜎2/𝜏2  =  1 
 Strong pessimistic prior: 𝑁(20, 8.942), ESS = 𝜎2/𝜏2 =  5 
 Weak optimistic prior: 𝑁(30, 202), ESS = 𝜎2/𝜏2  =  1 
 Strong optimistic prior: 𝑁(30, 8.942), ESS =
𝜎2
𝜏2
=  5, 
where “weak” denotes ESS = 1 and “strong” denotes ESS = 5, while “pessimistic” means 
𝜃 =  𝜇0 and “optimistic” means 𝜃 =  𝜇1. The numeric results are presented in Table 3.2, 
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and the stopping boundaries for the ten-stage design is shown in the Figure 3.1. It has been 
shown that the results are fairly robust. All four priors gave a similar smallest sample size 
required. It is interesting that the 𝑃𝑇 that leads to the minimax design is more similar with 
the same prior. When we use pessimistic priors, 𝑃𝑇 for the strong prior is smaller than the 
weak prior; while when we use optimistic priors, 𝑃𝑇 for the strong prior is larger than the 
weak prior. The stopping boundaries are getting closer to each other after the 3rd interim 
look, which is intuitive in practice since the more information obtained, the more precise 
evidence we can apply to make our trial decision. We don’t suggest make a decision too 
early based on very limited information. 
3.4.2 Case Study 
In this section, we apply this multi-stage design to the same unpublished trial 
illustrated in Wason et al. [5]. In this unpublished trial, the primary endpoint was a binary 
response rate and was originally designed as a Simon’s two-stage design. In Wason’s 
design, they transformed the binary endpoints into continuous variable using a standard 
normal distribution transformation (shown in the appendix).  Therefore, 𝜇0 = −7.6 and 
𝜇1 =  11.1, with known 𝜎 = 36.4. Under this setup, Wason’s optimal continuous design 
yielded around 50% reduction in total sample size when compared to the design using 
binary response rate.  
We apply our Bayesian PP design for this trial scenario. In particular, 𝜇0 = −7.6, 
𝜇1 =  11.1 and 𝜎 = 36.4. We chose the prior as 𝑁(−7.6,  36.4
2) and set the same type I 
and II error rates as 0.05 and 0.1, respectively. We set 𝑃𝐿 = 0.1, 𝑃𝑈 = 0.95 and searching 
range for 𝑃𝑇 to be [0.9 −  0.99]. We tested our design in two settings. Setting 1: equally 
spaced with 5 stages; Setting 2: equally spaced with 10 stages. The numeric results are 
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presented below in Table 3.3, and the stopping boundaries are shown in Figure 3.2. The 
minimax design yields a total sample size for the 5-stage design of 40, with 𝑃𝑇  determined 
to be 0.953. When the number of stages increases to 10, the minimal total sample size 
required to meet both type I and type II error rates increases to 46. The stopping boundaries 
for both settings are shown in figure 3.2. For example, in terms of 5-stage design, after 8 
patients are enrolled at the end of first stage, if the average tumor shrinkage is greater than 
22.95 we should stop the trial early for efficacy. If the average tumor shrinkage is less than 
-12.34, we should stop the trial early for futility, otherwise trial should continue to the 
second stage.  
We also assess the operating characteristics when the interim looks are not equally 
spaced. The numeric results are shown in Table 3.4. The first row in Table 3.2 is the equally 
spaced design. The second row is for stopping the trial after approximately10%, 30%, 50%, 
70% and 100% of the patients are enrolled. The third row is to stop the trial after 
approximately 10%, 20%, 30%, 40%, 100% of the patients are enrolled. The last row is to 
stop the trial after approximately 60%, 70%, 80%, 90% and 100% of the patients are 
enrolled. In these four scenarios, 𝑃𝑇 is quite similar, meaning it may not affect the design 
when the searching range was given. However, the one with the first interim look at 60% 
of the patients are enrolled yields the smallest total sample, while the one with the first 4 
interim looks before 50% of the patients are enrolled gives the largest total sample size.  
 
3.5 Discussion 
A group-sequential approach in clinical trials is usually to analyze the interim data 
after groups of patients were enrolled. It is usually more flexible and efficient than the 
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design with fixed sample size. In this paper, we extended Lee and Liu’s PP design for 
binary outcomes and proposed a multi-stage design for continuous endpoints based on 
predictive probability. The current design allows to stop the trial early either due to futility 
or efficacy, while maintaining the frequentist operating characteristics at the same time.  
If continuous monitoring of the trial is desired, information from a certain number 
of patients after the trial starts is needed for the first interim analysis. Lee and Liu suggest 
the 1st interim look should happen after 10% of the total patients are enrolled [37]. As we 
show in the case study, as more patients are analyzed in earlier stages, fewer total patients 
are required. In addition, when investigators choose equal sample size for each stage, when 
the effect size is large, the sample size at each stage may not be exactly the same due to 
rounding precision. For example, in Table 1, when the effect size equals to 1 and number 
of stages is 8. The total sample size required is 11, with 1 in each stage for the first 7 stages 
and 4 in the last stage. However, this situation may not be ideal and reasonable in practice. 
We would rather set larger percentage at the beginning of the trial. For example, regarding 
the design with 8-stage design and effect size of 1, if we put 3 patients in the first stage and 
then 1 for each from stage 2 to stage 8, the total sample size of 10 yields the desired 
minimax design.   
There are several limitations in this current proposed design. Firstly, in this paper, 
we only assessed equal spaced interim looks from 3- to 10-stages. Although our R code 
can accommodate user-defined unequal spaced interim looks, we did not compare the 
operating characteristics from those unequally spaced interim looks with those design 
scenarios presented, except the case study in this manuscript. Therefore, one of the future 
directions is to explore how to space the interim looks during the whole trial to achieve the 
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most desirable design, and how it will affect the design properties. Secondly, due to the 
current algorithm, we can only accommodate up to 40 interim looks during the trial due to 
the dependency of the R2Cuba package [77]. We plan to extend it into ‘real’ continuous 
monitoring in the future, although we need to determine how it is realistic in practice to 
monitor the trial continuously. In practice, the necessity of continuous monitoring depends 
on several factors, such as effect size, the overall sample size required, the timing of 
endpoints collection during the trial as well as trial resources and staffing.  Thirdly, we 
only explored optimistic and pessimistic conjugated normal priors. Therefore, it would be 
interesting to assess how non-conjugated priors, both pessimistic and optimistic, will 
impact the results. Further, as we mentioned above in the manuscript, our grid searching 
strategy can only accommodate the minimax design due to computation time. It will be 
interesting to see how the probability of early termination under the null hypothesis and 
compare the expected sample size from the optimal design with the smallest sample size 
desired. We plan to optimize the code and incorporate it into our ongoing R package. 
In general, we have shown the results from a multi-stage design using predictive 
probability for continuous endpoints. We have shown that in a two-stage design, the total 
sample size reduced nearly by half when we used the continuous endpoints, instead of 
dichotomizing them into binary endpoints. When it was extended to a multi-stage design, 
the total sample required increases as the number of interim looks increases, which is 
common to other group sequential designs. However, the multi-stage design provides more 
flexibility and statistical efficiency when compared to the two-stage design. We developed 
R functions to perform this proposed design and the code will be available in an upcoming 
R package, but these functions are currently available upon request. As research rapidly 
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moves to incorporate more immunotherapies and targeted therapies, these designs will 
accommodate new types of outcomes while allowing for flexible stopping rules for futility 
and/or efficacy to continue to optimize trial resources and prioritize agents with compelling 
early phase data.  
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Table 3.1 Operating characteristics of minimax multi-stage design for continuous 
endpoints. For both designs below,  μ0  = 20,  μ1  = 30,  θ = μ0 = 20 , σ =
10, 12.5, 20 and 50, τ =  σ. 𝑃𝐿 = 0.1 and 𝑃𝑈 = 0.95.  
 
𝛼 = 0.05, 𝛽 = 0.2 
Effect size σ 𝐾 𝑃𝑇 𝑁𝑚𝑎𝑥 Type I Error Type II Error 
1.0 10 3 0.936 7 0.049 0.179 
 
 4 0.936 8 0.049 0.159 
  5 0.937 9 0.050 0.132 
  6 0.940 11 0.049 0.087 
  7 0.933 8 0.050 0.187 
  8 0.940 11 0.047 0.141 
  9 0.942 9 0.036 0.183 
  10 0.931 10 0.046 0.093 
0.8 12.5 3 0.942 12 0.050 0.156 
 
 4 0.940 11 0.050 0.194 
  5 0.942 13 0.050 0.147 
  6 0.943 13 0.049 0.165 
  7 0.942 13 0.049 0.165 
  8 0.942 15 0.050 0.138 
  9 0.941 17 0.047 0.126 
  10 0.930 10 0.044 0.155 
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Table 3.1 (Continued) 
𝛼 = 0.05, 𝛽 = 0.2 
Effect size σ 𝐾 𝑃𝑇 𝑁𝑚𝑎𝑥 Type I Error Type II Error 
0.5 20 3 0.948 28 0.050 0.185 
  4 0.950 29 0.049 0.191 
  5 0.951 30 0.049 0.193 
  6 0.952 33 0.049 0.171 
 
 7 0.952 33 0.050 0.183 
  8 0.952 33 0.050 0.179 
  9 0.952 32 0.049 0.190 
  10 0.950 34 0.048 0.125 
0.2 50 3 0.953 171 0.049 0.198 
 
 4 0.955 179 0.050 0.197 
  5 0.957 189 0.049 0.198 
  6 0.959 196 0.050 0.198 
  7 0.960 202 0.050 0.198 
  8 0.964 206 0.048 0.192 
  9 0.967 216 0.046 0.199 
  10 0.961 213 0.048 0.176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
  
Table 3.2 Operating characteristics of minimax designs with different priors. (Design 
parameters: μ0 = 20, μ1 = 30, σ = 20, α =  0.05, β = 0.2, 𝑃𝐿 = 0.1 and 𝑃𝑈 = 0.95). For 
simulation in this table, the effect size were set as 0.5.  
 
Prior 
N(𝜃, 𝜏2) 
K 𝑃𝑇 𝑁𝑚𝑎𝑥 Type I Error Type II Error 
Pessimistic Weak 3 0.948 28 0.050 0.185 
𝑁(20, 202) 4 0.950 29 0.049 0.191 
 5 0.951 30 0.049 0.193 
 6 0.952 33 0.049 0.171 
 7 0.952 33 0.050 0.183 
 8 0.952 33 0.050 0.179 
 9 0.952 32 0.049 0.190 
 10 0.950 34 0.048 0.125 
Optimistic Weak 3 0.960 27 0.049 0.200 
𝑁(30, 202) 4 0.962 29 0.050 0.196 
 5 0.964 30 0.049 0.195 
 6 0.966 30 0.049 0.200 
 7 0.966 32 0.049 0.187 
 8 0.969 32 0.048 0.198 
 9 0.970 33 0.048 0.199 
 10 0.966 37 0.045 0.176 
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Table 3.2 (Continued) 
Prior 
N(𝜃, 𝜏2) 
K 𝑃𝑇 𝑁𝑚𝑎𝑥 Type I Error Type II Error 
Pessimistic Strong 3 0.930 27 0.050 0.178 
𝑁(20, 8.942) 4 0.929 28 0.050 0.196 
 5 0.929 29 0.049 0.200 
 6 0.929 30 0.049 0.199 
 7 0.927 31 0.049 0.197 
 8 0.924 32 0.050 0.192 
 9 0.921 30 0.050 0.186 
 10 0.912 30 0.048 0.104 
Optimistic Strong 3 0.978 27 0.048 0.197 
𝑁(30, 8.942) 4 0.978 28 0.050 0.190 
 5 0.979 29 0.050 0.189 
 6 0.980 29 0.049 0.198 
 7 0.981 30 0.048 0.196 
 8 0.981 31 0.048 0.189 
 9 0.975 31 0.049 0.048 
 10 0.978 31 0.047 0.162 
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Figure 3.1: Stopping Boundaries for the 10-stage design with 4 different priors. In this scenario, the parameters are as follows: 𝜇0 =
20, 𝜇1 = 30, 𝜎 = 20, 𝑃𝐿 = 0.1, 𝑃𝑈 = 0.95, searching range for 𝑃𝑇  is [0.9, 0.99]. All the four designs meet the pre-specified type I and 
type II error rates (𝛼, 𝛽) = (0.05, 0.2).  
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Table 3.3 Operating characteristics of 5-stage and 10-stage Minimax design with equal space for case study. The searching range for PT 
is [0.9 – 0.99]. PL = 0.1 and PU = 0.95. μ0 = −7.6, μ1 =  11.1, σ = 36.4 . θ = μ0 = −7.6, τ =  σ = 36.4 and (α, β) = (0.05, 0.1).  
 
 𝑃𝑇 Nmax Type I Error Type II Error 
5-stage design 0.953 40 0.049 0.096 
10-stage design 0.954 46 0.047 0.097 
 
 
 
Table 3.4 Operating characteristics of 5-stage unequal space for case study. The searching range forPT is [0.9 – 0.99]. PL = 0.1 and PU =
0.95. μ0 = −7.6, μ1 =  11.1, σ = 36.4 . θ = μ0 = −7.6, τ =  σ = 36.4 and (α, β) = (0.05, 0.1).  
 
𝑁1 𝑁2 𝑁3 𝑁4 𝑁5 𝑃𝑇 Type I Error Type II Error 
8 16 24 32 40 0.953 0.049 0.096 
5 13 22 31 43 0.955 0.050 0.098 
5 9 14 18 45 0.958 0.050 0.100 
22 26 29 33 36 0.950 0.047 0.093 
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Figure 3.2: Stopping Boundaries for the 5-stage design and 10-stage design for case study. 
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CHAPTER FOUR 
PPSC: An R Package for Single-Arm Phase II Predictive Probability Design with 
Continuous Endpoints 
4.1 Abstract 
In practice, interim analyses are usually incorporated into a trial to stop the trial 
early either due to futility and/or superiority. Early stopping of the trial can prevent patient 
exposure to ineffective therapies or accelerate drug development if beneficial effects are 
observed. In the Bayesian framework, interim designs based on predictive probability 
provide a flexible way to monitor the trial continuously while incorporating the evidence 
from the current data and making inference for the future. We extended a predictive 
probability design for binary outcomes into a single-arm trial setting for continuous 
outcomes and provide both optimal and minimax designs. In this paper, we describe the 
usage and implementation of the R package PPSC, which aims to implement a grid search 
strategy to find the optimal and minimax designs for continuous outcomes based on 
predictive probability. The package PPSC contains two functions and provides the 
solutions for both two-stage and multi-stage designs. These two functions give clinical 
investigators and biostatisticians the flexibility to monitor the trial and provide the stopping 
boundaries for futility and efficacy when early stopping the trial is desired.  
Keywords: predictive probability; continuous outcome; interim design; phase II; R.  
 
4.2 Introduction 
A conventional phase II trial aims to evaluate the treatment effect of a drug or 
therapy being studied and identify the promising ones to carry on to the confirmative phase 
III trials. Interim strategies are of great importance in each stage of clinical trials. As 
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developed for protecting participants from unsafe drugs or to hasten the general 
implementation of a beneficial therapy, interim strategies can be utilized to stop the trials 
early either for safety, futility or efficacy [14]. 
Many statistical methods have been developed for phase II trial designs, for both 
two-stage and multi-stage designs, regarding different types of endpoints. For binary 
endpoints, Gehan  developed a two-stage design to stop the trial early due to futility if no 
response is observed from the first stage [18]. Simon proposed both optimal design and 
minimax design allowing one interim stop for futility [19]. Several extensions of Simon’s 
design have been proposed [20, 21, 78]. Recent years, Bayesian approaches have been 
widely applied in the clinical trial designs. In particular, Tan and Machin proposed a two-
stage design based on posterior distribution of the true response rate and Sambucini 
extended it into predictive version [29-31]. Dong et al. suggested a two-stage design 
incorporating both frequentist and Bayesian error rates [39].  
Regarding multi-stage designs, group-sequential designs are widely used in 
practice, in which groups of patients, either equally spaced or unequally spaced, are 
enrolled and the hypothesis is tested multiple times during accrual the trial. The most 
popular group sequential designs are O’Brian-Fleming’ design and Pocock’s design [62, 
63]. Jennison ad Turnbull provide an thorough overview of group-sequential methodology 
[74]. Under Bayesian framework, in particular, Lee and Liu developed a predictive 
probability design for the binary response rate to continuously monitor the trial [37].  
We extended Lee and Liu’s predictive probability design into a setting for 
continuous outcome. This paper introduces an R package, PPSC, which provides the 
implementation of our extended predictive probability designs. This package specifically 
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incorporates two types of designs: the two-stage design and the multi-stage design. The 
two-stage design is primarily for the purpose of early stopping due to futility, while it also 
has the capacity to stop early due to efficacy. The multi-stage design allows early stopping 
of the trial due to either futility or efficacy, which can accommodate up to 40 stages with 
39 interim looks.  
The paper is organized as follows. Section 4.3 describes the both two-stage design 
and multi-stage design as well as the trial decision rules. Section 4.4 details the 
implementation of the two main functions in the package and gives a series of examples of 
how to use the options in the functions. Section 4.5 discusses the limitations and future 
directions for current design and package.  
 
4.3 Methods 
For both two-stage and multi-stage designs, the hypothesis testing framework is as 
follows: 
𝐻0: 𝜇 ≤  𝜇0  vs. 𝐻1: 𝜇 ≥  𝜇1 
where 𝜇0  represents the maximum efficacy from the standard treatment or historical 
control, while  𝜇1 represents a target efficacy threshold from the treatment or therapy being 
investigated. Both designs meet pre-specified Type I and Type II error rate constraints.  
For illustration purposes, we use tumor shrinkage as an example of continuous 
outcomes. However, this design is not limited to tumor shrinkage. It could be used for 
changes in biomarkers, pre-post designs or any other continuous endpoints. We present 
this one example throughout for simplicity. Here, we define “tumor size change/tumor 
shrinkage” as the percentage decrease in the sum of the longest diameter of the target 
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lesions compared to baseline for each patient, with positive values denoting tumor 
shrinkage. We assume the average tumor shrinkage,  𝑋 , follows a normal distribution 
𝑁( 𝜇, 𝜎2),  with mean 𝜇 and known variance 𝜎2. We assume a normal conjugate prior 
distribution for 𝜇, 𝑁(𝜃, 𝜏2) and we use effective sample size for the prior (ESS), the ratio 
of likelihood variance to prior variance ( 
𝜎2
𝜏2
) for the normal case, to assign the amount of 
information for the prior [67]. For the purpose of simulation, we set ESS = 1, assuming 
very little knowledge is known before the trial starts. In practice, ESS and priors should be 
input from the investigators and represent the investigator’s previous knowledge of the 
tumor size change or endpoint being studied from standard treatment or historical control. 
We generalized the notation for the two-stage design to be a special case of the 
multi-stage design. We consider a single-arm trial with a total sample size of 𝑁𝑚𝑎𝑥 and 
total  𝐾 stages, where  𝐾 ≤  𝑁𝑚𝑎𝑥. When K = 2, it represents the two-stage design. At the 
end of 𝑖𝑡ℎ  stage, the number of patients enrolled in total is denoted as 𝑛𝑖 , where 𝑖 =
1, 2, … , 𝐾.  We denote the average tumor shrinkage for 𝑛𝑖 patients as ?̅?𝑛𝑖. Therefore, given 
the information from these current 𝑛𝑖 patients, the posterior distribution of the mean tumor 
shrinkage 𝜇 follows a normal distribution, with mean  
𝜎2𝜃
𝑛𝑖𝜏
2+𝜎2
+ 
𝑛𝑖𝜏
2
𝑛𝑖𝜏
2+𝜎2
?̅?𝑛𝑖 and variance 
𝜏2𝜎2
𝑛𝑖𝜏
2+𝜎2
. Thus, the average tumor shrinkage from the future 𝑚𝑖  patients, where 𝑚𝑖 =
 𝑁𝑚𝑎𝑥 − 𝑛𝑖, follows a normal distribution with mean 𝜇𝑝
∗  and 𝜎𝑝
∗2, where   
𝜇𝑝
∗ = 
𝜎2𝜃
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
+ 
𝑛𝑖𝜏
2
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
?̅?𝑛𝑖 +
𝑚𝑖𝜏
2?̅?𝑚𝑖
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
 
𝜎𝑝
∗2 = 
𝜏2𝜎2
(𝑚𝑖 + 𝑛𝑖)𝜏2 + 𝜎2
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We define 𝐵𝑖 = 𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) to measure the probability that the mean tumor 
shrinkage is larger than 𝜇0, given the mean tumor size change in current 𝑛𝑖 patients and 
future 𝑚𝑖 patients. We can conclude the treatment is efficacious when 𝐵𝑖 > 𝑃𝑇, where 𝑃𝑇 
is the posterior critical value at each stage and is usually assumed to be greater than 0.8. 
𝐵𝑖 =  𝑃𝑟𝑜𝑏(𝜇∗ > 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) = 1 − 𝑃𝑟𝑜𝑏(𝜇∗ ≤ 𝜇0|?̅?𝑛𝑖 , ?̅?𝑚𝑖) 
= 1 −  𝛷 (
𝜇0− 𝜇𝑝
∗
𝜎𝑝
∗ ) > 𝑃𝑇  
where 𝛷 ( ∙) represents the cumulative density function (CDF) of the standard normal 
distribution. The above inequality (1) can be derived into an inequality of ?̅?𝑚𝑖 regarding 
𝜃𝑇.  
?̅?𝑚𝑖 >
((𝑛𝑖+𝑚𝑖)𝜏
2+𝜎2)(𝜇0− 𝜎𝑝
∗𝛷−1(1−𝑃𝑇))− 𝜎
2𝜃−𝜏2𝑛𝑖?̅?𝑛𝑖
𝑚𝑖𝜏
2 = 𝛿  
The posterior predictive distribution of tumor size change from the future 𝑚 patients also 
follows a normal distribution 𝑁(𝜇𝑝, 𝜎𝑝
2) , with  𝜇𝑝 = 
𝜎2𝜃
𝑛𝑖𝜏
2+𝜎2
+ 
𝑛𝑖𝜏
2
𝑛𝑖𝜏
2+𝜎2
?̅?𝑛𝑖  and 𝜎𝑝
2 =
 
𝜎2
𝑚𝑖
+ 
𝜏2𝜎2
𝑛𝑖𝜏
2+𝜎2
.  
Based on all the information above, we can then define the predictive probability (𝑃𝑃)  
Predictive probability (𝑃𝑃) = 𝑃𝑟𝑜𝑏(?̅?𝑚𝑖 > 𝛿|?̅?𝑛𝑖) 
= 1 − 𝑃𝑟𝑜𝑏(?̅?𝑚𝑖 ≤ 𝛿|?̅?𝑛𝑖) = 1 −  𝛷 (
𝛿 − 𝜇𝑝 
𝜎𝑝
)  
(1) 
(2) 
(3) 
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A high 𝑃𝑃 means that given current data, the treatment is likely to be efficacious by the 
end of the study; whereas a low 𝑃𝑃 suggests that the treatment may not have sufficient 
activity. Therefore, we use 𝑃𝑃 to make the decision during the interims in the trial.  
 If  𝑃𝑃𝑖 < 𝑃𝐿, stop the trial and reject the alternative hypothesis; 
 If  𝑃𝑃𝑖 > 𝑃𝑈, stop the trial and reject the null hypothesis; 
 Otherwise, continue to the next stage.  
𝑃𝑃𝑖 can also be transformed into ?̅?𝑛𝑖, and the trial decision rules can be made according 
to the futility and efficacy boundaries at the end of each stage.   
Although our design stopping boundaries are based on Bayesian predictive 
probabilities, we additionally restrict our designs to satisfy pre-specified type I and type II 
error rates constraints. Therefore, we need to calculate the probability of rejecting the null 
hypothesis at each stage. The detailed calculations for type I error rates and power are 
documented in Chapter 2 and 3. 
 
4.4 Use of the package PPSC 
Package PPSC depends on three libraries: R2Cuba, cubature and ggplot2 [76, 77, 
79]. Packages cubature and R2Cuba are employed to conduct the multidimensional 
integration either using direct numeric integration or Monte Carlo algorithm. When the 
design has more than three stages, integration using Monte Carlo algorithm is much faster 
than numeric integration. Package ggplot2 is utilized to plot the design stopping boundaries. 
Both designs give clinical investigators and biostatisticians the flexibility to monitor the 
trial and stop the trial early when necessary. 
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Package PPSC contains two functions, par2stage and parmultistage. Function 
par2stage conducts a single-arm PP design, which incorporates one interim look, allowing 
for early stopping only due to futility. Function parmultestage performs a single-arm PP 
design allows for early stopping due to both futility and superiority, and currently allows 
for up to 40 interim looks. Regardless of design selected, input options are described in 
Table 4.1 and Table 4.2.  
For both functions, there are several arguments in common. To implement the two 
designs, the users should specify a couple of parameters: the likelihood standard deviation 
“sigma” (𝜎); the mean “theta” (𝜃) and standard deviation “tau” (𝜏) for the normal conjugate 
priors, which represents the previous knowledge about the endpoint from the investigators; 
the null value “mu0” (𝜇0) and alternative value “mu1” (𝜇1) for the hypothesis testing; the 
low and high boundaries for the posterior probability (𝑃𝑇) , “pTlow” and ”pThigh”, as well 
as the searching increment for (𝑃𝑇), “pTby”. As defined in Lee and Liu’s design, 𝑃𝑇 is 
usually a large number between [0.8, 1], while Dong et al. suggest a larger number such as 
0.95 [37, 39]. The default setting is “pTlow = 0.9, pThigh = 0.99 and pTby = 0.01”. For 
the two-stage design, users also need to specify the low and high boundaries for the 
predictive probability (𝑃𝐿), “pLlow” and ”pLhigh”, as well as the searching increment for 
(𝑃𝐿), “pLby”. 𝑃𝐿 is usually a small number below 0.1. The default setting is “pLlow = 0.01, 
pLhigh = 0.1 and pLby = 0.01”. Although two-stage design is primarily for early 
termination due to futility, the trial can also stop early for efficacy. To do so, the user can 
specify the upper boundary for the predictive probability (𝑃𝑈), “pU”, which is usually a 
large number greater than 0.9. The default value is 0.95. In addition, for the multi-stage 
design, users have the flexibility of specifying the following parameters: if the trial is 
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continuously monitored “continuous”, with the default value “F”; the number of interims 
looks involved in the trial “num.interim”, with the default value “num.interim = 2” for the 
3-stage design; if the number of patients at each stage is the same “equal.space”, with 
default setting “equal.space = T” for the same number of patients at each stage. Further, 
for both designs, the users need to specify the type I and type II error rates constraints, 
“pre.typeIerror” and “pre.typeIIerror”. The default settings are “pre.typeIerror = 0.05” and 
“pre.typeIIerror = 0.2”. The plot for stopping boundaries can be outputted with the 
argument “plot_yes” being “T”. 
Another argument for both function is “plot_yes”, for which if the value is “T”, the 
plot for stopping boundaries is outputted. 
4.4.1 Two-stage design for early stopping due to futility: use of par2stage 
Example 1: 
Consider the situation where the standard therapy or historical control will lead the 
tumor shrinkage up to 20% shrinkage and the clinical investigators want to test if the new 
therapy will improve the tumor shrinkage to at least 30%. The trial only allows for early 
stopping due to futility. Therefore, we set pU = 1. The likelihood standard deviation in this 
example is assumed to be 20, which should be input from the investigator or from historical 
control data. If we assume little information is known before the trials starts, we use ESS 
= 1. Thus, theta = 20 and tau = 20.  The searching range for pL is to be [0.01, 0.1] and for 
pT is to be [0.9, 0.99]. The increment for grid search is 0.01 for both pT and pL. The pre-
specified type I error rate is set to 0.05, and type II error rate is set to 0.2. The R code 
necessary to run this scenario is: 
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Example1 <- par2stage (sigma = 20, tau = 20, theta = 20, mu0 = 20, mu1 = 30,  
pTlow = 0.90, pThigh = 0.99, pTby = 0.01, pLlow = 0.01, pLhigh = 0.1, pLby = 0.01, pU 
= 1, pre.typeIerror = 0.05, pre.typeIIerror = 0.2, plot_yes = T) 
The output is a list containing two elements, which give the operating 
characteristics for both optimal design and minimax design. In terms of the optimal design, 
the total sample size required is 27 with 11 for the first stage. The futility boundaries for 
first and second stage are 20.681 and 26.447. The corresponding type I and type II error 
rates are 0.044 and 0.199. The pT and pL that yield the optimal design are 0.95 and 0.1. 
The minimax design yields a very similar parameter combination, with 26 as the total 
sample size, 14 as the sample size for the first stage, 21.048 and 26.575 as the futility 
boundaries. 
$`Optimal Design` 
[1] 
Total Sample Size         27 
Sample Size for the First Stage         11 
Futility Boundaries at the End of the First Stage         20.681 
Futility Boundaries at the End of the Second Stage         26.447 
Probability of Early Termination          0.545 
Expected Sample Size under the null         18.281 
Type I Error          0.044 
Type II Error          0.199 
pT          0.950 
pL          0.100 
[2] 
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$`Minimax Design` 
[1] 
Total Sample Size         26 
Sample Size for the First Stage         14 
Futility Boundaries at the End of the First Stage         21.048 
Futility Boundaries at the End of the Second Stage         26.575 
Probability of Early Termination          0.578 
Expected Sample Size at null         19.067 
Type I Error          0.045 
Type II Error          0.200 
pT          0.950 
pL          0.060 
[2] 
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Example 2: 
Although the current version of the software is not designed to search for the 
desired pU within a user-defined range, it has the capacity to allow for early stopping due 
to efficacy. The user can specify pU, which is usually a large positive number between 0 
and 1, for example, above 0.9. If the predictive probability is greater than pU, say 0.95, 
indicating that given the information from the current data, we will have 95% probability 
to conclude that the treatment is efficacious by the end of the study, if data had the same 
trend. Therefore, in the same scenario for example 1, if we designed the trial which to allow 
for early stopping either due to futility or superiority, the R code and the output are as 
follows: 
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Example2 <- par2stage (sigma = 20, tau = 20, theta = 20, mu0 = 20, mu1 = 30,  
pTlow = 0.9, pThigh = 0.99, pTby = 0.01, pLlow = 0.01, pLhigh = 0.1, pLby = 0.01, pU = 
0.95, pre.typeIerror = 0.05, pre.typeIIerror = 0.2, plot_yes = T)  
$`Optimal Design` 
[1] 
Total Sample Size         27 
Sample Size for the First Stage         10 
Futility Boundaries at the End of the First Stage         20.215 
Futility Boundaries at the End of the Second Stage         26.447 
Efficacy Boundaries at the end of the First Stage         35.340 
Efficacy Boundaries at the End of the Second Stage          26.447 
Probability of Early Termination          0.521 
Expected Sample Size at null         18.140 
Type I Error          0.048 
Type II Error          0.197 
pT          0.950 
pL          0.100 
[2] 
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$`Minimax Design` 
[1] 
Total Sample Size         26 
Sample Size for the First Stage         13 
Futility Boundaries at the End of the First Stage         20.923 
Futility Boundaries at the End of the Second Stage         26.575 
Efficacy Boundaries at the end of the First Stage         33.388 
Efficacy Boundaries at the End of the Second Stage          26.575 
Probability of Early Termination          0.574 
Expected Sample Size at null         18.538 
Type I Error          0.048 
Type II Error          0.199 
pT          0.950 
pL          0.070 
[2] 
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The design operating characteristics are very similar to the design that only allows 
for early stopping due to futility. In the output, there are two more operating characteristics 
“Efficacy Boundaries at the end of First Stage” and “Efficacy Boundaries at the end of 
Second Stage”. The interpretation here is:  in terms of the optimal design, after enrolling 
10 patients, if the average tumor shrinkage is less than 20.215% , we should stop the trial 
early for futility; if the average tumor shrinkage is greater than 35.340%, we should stop 
the trial early for efficacy; otherwise we should continue to the second stage and enroll 10 
additional patients. Both optimal designs (Example 1 and Example 2) yield a total sample 
size of 27, and both minimax designs yield a total sample size of 26. pL and pT were also 
very similar for both optimal and minimax designs. 
According to our simulation experience, the operating characteristics arising from 
the design allowing for early stopping due to efficacy will get close to those from the futility 
design when pU gets close to 1. When pU is smaller, say 0.9, the sample size required for 
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the first stage will be larger. The probability of early termination also increases. The total 
sample size will be 26 with the probability of early termination 0.722. 
Example 1 and 2 explain the usage of function par2stage to perform the two-stage 
design. Both optimal design and minimax design are included in the output. The stopping 
boundaries are also displayed if the value for “plot_yes” argument is “T”. 
4.4.2 Multi-stage design for early stopping due to both futility and efficacy: use of 
parmultistage 
Example 3: 
Consider the same scenario from the previous examples in the two-stage design 
setting. The investigators want to incorporate more than one interim look during the entire 
trial. The standard therapy or historical control will lead to tumor shrinkage up to 20%, and 
the clinical investigators want to test if the new therapy will improve the tumor shrinkage 
up to at least 30%. All the other parameters are assumed to be the same. 
In current version, for the multistage design, we are only allowed to search the 
range for pT, but not for pL and pU, due to intensive computation time. The user should 
pre-specify a single value for pL and pU, for example, pL = 0.1 and pU = 0.95. Usually, as 
mentioned above, pL is a small number and pU is a large number between 0 and 1.  The 
pre-specified type I error rate and type II error rate were still set to be 0.05 and 0.2. In 
addition, this current version can only display the minimax design also due to the 
computing time and searching strategy.  If the investigators want to incorporate 3 interim 
looks during the entire trial with sample size equally spaced and the searching range for pT 
is still set as [0.9, 0.99], the R-code to execute is as follows: 
Example3 <- parmultistage(continuous = F, first.look = NULL, num.interim = 3 , 
equal.spaced = T , user.p = NULL , sigma = 20, tau = 20, mu0 = 20, mu1 = 30 , theta = 20, 
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pTlow = 0.9, pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror = 0.05 , 
pre.typeIIerror = 0.2, plot_yes = T) 
[[1]] 
Minimax Design 
Cumulative sample size for each interim look 7   14   21   29 
Futility Boundaries         18.00    21.42    23.34    26.21 
Efficacy Boundaries        38.25    32.87    30.09    26.21 
Probability of Early Termination       0.84 
Expected Sample Size under H0        24.67 
Type I Error       0.05 
Type II Error 0.19 
pT 0.95 
[[2]] 
In the R arguments, just to set the num.interim equal to 3, which is the number of 
interim looks desired during the trial, and to set equal.spaced = T, indicating the same 
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number of patients at each stage is desired. Sometimes, when we set the interim looks 
equally spaced through the trial, sample size in the last stage may deviate slightly from 
previous stages. In this example, the sample size for the last stage is 8, instead of 7 as the 
first three stages. This discrepancy is due to rounding errors. If we set plot_yes = T, the 
output from parmultistage function is a list containing two elements. The first element is 
the operating characteristics for the minimax design resulting from the user-specified 
parameters, including the sample size and futility/ efficacy boundaries for each interim 
look, probability of termination, expected sample size under the null hypothesis and type 
I/II error rates. The second element is a plot for stopping boundaries, with y-axis being the 
upper and lower boundaries for trial stopping rules, and x-axis being the cumulative 
number of patients at each interim look. To hide the plot, set plot_yes equal to F.  
Example 4: 
If the investigators prefer not to space looks at the data equally, they can also define 
the cumulative proportion of the sample size regarding each interim look. For example, 
instead of equally spaced interim looks, the investigators can set user.p = c(0.1, 0.4, 0.8, 
1.0)  and equal.spaced  = F, if they want to analyze the data from the trial after 10%, 40% , 
80% and 100% of the patients are enrolled. They can stop the trial at each of the interim 
looks either due to futility or efficacy. The R code is as follows:  
Example4 <- parmultistage(continuous = F, first.look = NULL, num.interim = 3 , 
equal.spaced = F, user.p = c(0.1, 0.4, 0.8, 1.0), sigma = 20, tau = 20, mu0 = 20, mu1 = 30 , 
theta = 20, pTlow = 0.9, pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror 
= 0.05 , pre.typeIIerror = 0.2, plot_yes = T) 
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The output is as follows:  
[[1]] 
                                                        Minimax Design 
Cumulative sample size for each interim look                 4   13   26   32 
Futility Boundaries                          14.42    20.97    24.15    26.29 
Efficacy Boundaries                         44.56    33.75    29.13    26.29 
Probability of Early Termination     0.9 
Expected Sample Size under H0      24.9 
Type I Error                                      0.04 
Type II Error                                     0.2 
pT                                                      0.96 
 
[[2]] 
 
The results are different from the design with equally spaced interim looks. The 
total sample size required is larger than the design with equally spaced interim looks. Given 
different sample sizes at each interim look, as well as different 𝑃𝑇 yielding the minimax 
design, the futility and efficacy boundaries are also different between two designs.  
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Example 5: 
If the investigators want to continuously monitor the trial, especially when the 
effect size is large, they can specify the argument “continuous = T”. In addition, they can 
specify the proportion of the total sample size they plan for the first interim look. For 
example, when the effect size is 1, that is sigma = tau = 10, and all the other parameters the 
same as previous examples, the investigators want to monitor the trial continuously after 
50% of the patients are enrolled. In this scenario, we can specify the arguments of 
“continuous = T” and “first.look = 0.5”. The R code necessary to run this scenario is 
Example5 <- parmultistage(continuous = T, first.look = 0.5, num.interim = NULL , 
equal.spaced = F, user.p = NULL, sigma = 10, tau = 10, mu0 = 20, mu1 = 30 , theta = 20, 
pTlow = 0.9, pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror = 0.05 , 
pre.typeIIerror = 0.2, plot_yes = T) 
 
The output is as follows:  
[[1]] 
                                                        Minimax Design 
Cumulative sample size for each interim look                 4   5   6   7 
Futility Boundaries                          22.48    23.46    24.42    26.28 
Efficacy Boundaries                        32.50    30.63    28.98    26.28 
Probability of Early Termination     0.9 
Expected Sample Size under H0      6.70 
Type I Error                                      0.05 
Type II Error                                     0.19 
pT                                                      0.94 
 
[[2]] 
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4.5 Discussion 
In this paper, we detailed the usage and implementation of the package PPSC 
corresponding to our single-arm predictive probability two- and multi- stage design for 
continuous outcomes. Package PPSC is an R package that provides a grid search for 
desired optimal and minimax design for continuous normal outcome based on predictive 
probability. Both optimal and minimax designs satisfy pre-specified type I and type II error 
rates. Package PPSC can be utilized to monitor the trial and stop the trial early either due 
to futility or efficacy. The function to conduct the two-stage trial is originally designed for 
futility trial, while it has the capacity to accommodate for early stop due to superiority.  
The function to conduct the multi-stage design can accommodate the situations with equal 
sample size at each stage, unequal sample size at each stage, and continuous monitoring of 
the trial.  
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On the other hand, there are several limitations to the current version of Package 
PPSC. First, Package PPSC is currently available only for normally distributed outcomes 
with conjugated priors. Second, in terms of multi-stage design, especially for the purpose 
of continuous monitoring, this version can only incorporate up to 40 stages due to the 
current package R2Cuba for multidimensional numerical integration [77]. Third, for two-
stage design, the package PPSC yields both optimal design and minimax design in the 
output. A user-defined range for 𝑃𝑇 and 𝑃𝐿  is searched to find both optimal and minimax 
designs. However, only minimax design is shown for multi-stage setting, due to the grid 
searching strategy and algorithm we employed. In the multi-stage setting, we restrict 𝑃𝐿 
and 𝑃𝑈  as a user-defined value and search for a user-defined range for 𝑃𝑇  to find the 
minimax design.  
In summary, we extended Lee and Liu’s predictive probability approach into two-
stage and multi-stage setting for continuous endpoints. In practice, these two designs are 
more relevant for treatment effects with short observation time. In the scenario where the 
treatment effect will take a long period, such as several weeks or months, to observe, this 
design is not quite useful. That is when the long-time treatment effect is expected in 
practice, patients will have been enrolled in later stages in the trial, since the patients will 
generally recruited continuously. Of course, it also depends on the institutes and recourses 
to enroll patients. We also developed an R package PPSC to implement the described 
designs. This package will be submitted to CRAN shortly after completion of this study 
and will then be freely accessible in R. All necessary functions are available upon request.  
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Table 4.1 Input options for function par2stage 
Name Role 
sigma The standard deviation from the user pre-specified normal likelihood 
function. 
tau The standard deviation from the user pre-specified normal prior 
distribution. 
theta The mean from the user pre-specified normal prior distribution.  
mu0 The maximum uninteresting mean from the null hypothesis. 
mu1 The minimum interesting mean from the alternative hypothesis. 
pTlow The lower boundary for searching range of 𝑃𝑇. 𝑃𝑇 is a value above 0.8. 
If the searching range for 𝑃𝑇 is from 0.9 to 0.99, then pTlow = 0.9. 
pThigh The higher boundary for searching range of 𝑃𝑇. 𝑃𝑇 is a value above 0.8. 
If the searching range for 𝑃𝑇 is from 0.9 to 0.99, then pThigh = 0.99. 
pTby The searching increment for 𝑃𝑇 . 
pLlow The lower boundary for searching range of 𝑃𝐿 . 𝑃𝐿  is usually a small 
value below 0.1. If the searching range for 𝑃𝐿 is from 0.01 to 0.1, then 
pLlow = 0.01. 
pLhigh The higher boundary for searching range of 𝑃𝐿. 𝑃𝐿 is usually a small 
value below 0.1. If the searching range for 𝑃𝐿 is from 0.01 to 0.1, then 
pLhigh = 0.1. 
pLby The searching increment for 𝑃𝐿. 
pU The efficacy boundary for predictive probability, which is usually a 
value above 0.9. 
pre.typeIerror The user pre-specified nominal type I error rate constraint. 
pre.typeIIerror The user pre-specified nominal type II error rate constraint. 
plot_yes The option to choose if displaying the stopping boundary plot. 
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Table 4.2 Input options for function parmultistage 
Name Role 
continuous The option to choose continuous monitoring or not. The default value 
is F.  
first.look The proportion of the total sample for the first interim look. The default 
value is NULL. The user should specify a number when continuously 
monitoring is desired.  
num.interim The number of interim looks during the trial. 
equal.space The option to set equally spaced interim looks. The default value is T. 
user.p The user defined proportion of sample size for each interim looks. 
sigma The standard deviation from the user pre-specified normal likelihood 
function. 
tau The standard deviation from the user pre-specified normal prior 
distribution. 
theta The mean from the user pre-specified normal prior distribution.  
mu0 The maximum uninteresting mean from the null hypothesis. 
mu1 The minimum interesting mean from the alternative hypothesis. 
pTlow The lower boundary for searching range of 𝑃𝑇. 𝑃𝑇 is a value above 0.8. 
If the searching range for 𝑃𝑇 is from 0.9 to 0.99, then pTlow = 0.9. 
pThigh The higher boundary for searching range of 𝑃𝑇. 𝑃𝑇 is a value above 0.8. 
If the searching range for 𝑃𝑇 is from 0.9 to 0.99, then pThigh = 0.99. 
pTby The searching increment for 𝑃𝑇 . 
pL The user pre-specified value for 𝑃𝐿 , which is usually a small value 
below 0.1. 
pU The user pre-specified value for 𝑃𝑈 , which is usually a large value 
above 0.9. 
pre.typeIerror The user pre-specified nominal type I error rate constraint. 
pre.typeIIerror The user pre-specified nominal type II error rate constraint. 
plot_yes The option to choose if displaying the stopping boundary plot. 
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CHAPTER FIVE 
Summary and Conclusion 
5.1 Conclusion 
Phase II trials aim to identify promising agents or therapies to move forward to 
confirmative randomized phase III trials. In practice, RECIST criteria is commonly applied 
to categorize the tumor shrinkage into complete response, partial response, progressive 
disease and stable disease [1]. Response rate, which is the combination of complete and 
partial response, with at least a 30% decrease in the sum of the longest diameter of the 
target lesions, is usually used as a secondary endpoint in most of the cancer trials. However, 
as shown in the previous studies, this dichotomization not only leads to loss of statistical 
efficiency, but greatly increases the required sample size [5, 54-56, 58].  
Interim strategies are of great importance in each stage of oncology clinical trials, 
and at least one interim look is usually encouraged when designing the trial. The 
purpose of interim looks is to terminate the trial early for safety, futility, or efficacy, 
and to facilitate the trial process and protect patients’ clinical benefits [14]. Two-stage 
design is widely used in phase II trials, one of which is Simon’s two-stage design in a 
single-arm setting for binary outcomes, such as response rate [19]. It has been extended 
in many different ways and has been summarized in the introduction part. Regarding 
multi-stage designs, the group-sequential approach is usually used in practice. A group-
sequential design for clinical trial is usually to analyze the interim data after groups of 
patients are enrolled. In this scheme, the number of patients at each stage is pre-specified 
and the trial continues as long as the underlying test statistics keeps within a specified 
boundary. In the randomized setting, group sequential designs are well developed and 
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widely applied in practice to identify and select new therapies [62, 63, 74]. For single-arm 
settings, in particular, Chang et al. proposed a group-sequential design for binary outcomes 
with minimized average expected sample size under the null and alternative hypotheses in 
phase II trials under the frequentist framework [80]. When compared with frequentist 
designs, Bayesian designs are more flexible. Lee and Liu proposed a predictive probability 
design, on which we developed our researches [37].  
In this dissertation, we proposed a two-stage design and a multi-stage design for 
continuous endpoints based on predictive probability and developed an R package for these 
two designs. The two-stage design is mainly focused on futility early termination while it 
has the capacity to stop for efficacy. The multi-stage design has the flexibility to allow 
early stopping either due to futility or efficacy. Both designs are flexible and user-friendly. 
The users can choose to monitor the trial continuously, or to monitor the trial with pre-
specified number of stages, in which the users have the options to set equal or unequal 
proportions of patients at each stage. Both designs meet pre-specified type I and type II 
error rate constraints.  
For both design options, we obtained similar decreased sample size as in previous 
studies, when using tumor shrinkage instead of response rate, as continuous variable and 
maintained the frequentist operating characteristics at the same time [5, 56]. We also 
explored and evaluated the roles of priors on the effect of the design operating 
characteristics. The results were shown to be fairly robust, although the comparison was 
illustrative but not conclusive. Assessed priors yielded similar sample sizes and other 
operating characteristics were slightly different. We also compared our results with designs 
based on posterior designs, and the results were very similar. However, when compared 
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with posterior probability design, this predictive probability approach has the advantages 
that it mimics the decision making process in reality and more intuitive. It answers the 
question that if additional data are collected, is the trial likely to show convincing evidence 
against the null hypothesis and in favor of the alternative hypothesis. The predictive 
probabilities approach is able to model the endpoint using earlier information that is 
informative about the final outcome. 
 
5.2 Strength and Limitations 
Strengths: 
In general, multi-stage is usually more efficient than two-stage or three-stage design. 
It is more efficient to stop the trial early for futility or superiority, which will save resources, 
protect patients, and accelerate the process of drug development. When compared with 
designs using binary outcomes, using continuous endpoints utilize more information from 
the data and, therefore, reduce the sample size. Both of our designs based on predictive 
probability, while maintaining the frequentist operating characteristics.  
One of the major strengths for this study is the flexibility to implement and making 
it an appealing alternative to other designs. In terms of two-stage design, the users have the 
option to stop the trial early only due to futility, or to stop the trial early due to efficacy 
with a specific value of 𝑃𝑇 . Regarding the multi-stage design, it allows continuous 
monitoring up to 40 stages. It is particularly useful when the effect size is large, and the 
investigators want to monitor the trial continuously. Further, this multi-stage design allows 
the flexibility of setting either equal or unequal numbers of patients at each stage when the 
effect size is moderate or small. To choose the design with equal numbers of patients at 
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each stage, the users just need to specify the number of interim looks they prefer. On the 
other side, if the users would like designs with unequal sample size for each stages, they 
can specify the cumulative proportion of the total sample size at each interim look.  
Another strength for this current study is that although the trial stopping boundaries 
are obtained from the predictive probability given the information from current data, which 
resembles more closely to the decision making process of conducting clinical trials in 
practice, it relies on parameters 𝑃𝐿, 𝑃𝑈 and 𝑃𝑇 to control the type I and type II error rate 
constraints in the meanwhile. With this hybrid setting, our designs were shown to possess 
the desirable operating characteristics and maintain both type I and type II error rates. 
Further, it has been shown that our design gave fairly robust results across different 
priors. The choice of priors is important in Bayesian clinical trial designs. We compared 
the results across “weak/strong” and “optimistic/ pessimistic” priors and all the results were 
very similar across different prior combinations, although more thorough assessment of 
priors’ effect, especially those non-conjugated priors, should be conducted in the future.  
Another strength is that we develop an R package PPSC to implement both two-
stage and multi-stage design. It is important to have a user-friendly tool available, which 
makes the two designs accessible in the future for the collaboration between biostatisticians 
and investigators.  
Limitations:  
There are several limitations in current two-stage and multi-stage designs, which 
we plan to address in the future. Firstly, for both designs, we assume the standard deviation 
𝜎 for the likelihood function of the studying continuous endpoint is known, in line with 
previous studies. It is reasonable, since in practice this value could be obtained from 
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precious trials or preclinical studies. However, when there is little prior information is 
available, especially for those novel drugs or biomarkers, it is not a valid assumption. Thus, 
unknown variance may be explored in the future. Secondly, prior are important in Bayesian 
clinical trial designs. It is always challenging and controversial to choose a suitable prior 
on the parameter of interest. For both designs, we only assessed the conjugate priors for 
the mean, assuming variance is known, and explored a little bit on the roles of pessimistic 
and optimistic priors. There could be clinical situations where the prior does not follow a 
normal distribution and thus the resulting posterior does not have a closed form.  More 
exploration is needed in this regard. We plan to look at other non-normal priors, such as 
log-normal distributions in the future. 
In terms of the multistage design, although our R package has the flexibility for 
user-defined sample size for each interim look, we need to set the value of 𝑃𝐿 and 𝑃𝑈 and 
only search for 𝑃𝑇  to find the desired design. In addition, we need to do a thorough 
evaluation on how to space the interim looks to achieve the most desirable design and how 
it will affect the design properties. Further, our grid searching strategy can only 
accommodate minimax design due to computation time due to the grid search strategy we 
employed. It will be interesting to see how the probability of early termination under the 
null hypothesis and compare the expected sample size from the optimal design with the 
smallest sample size desired. 
 
5.3 Future Directions 
We plan to extend this current study in different directions. There are several future 
directions in common for both two-stage design and multi-stage designs. First, since 
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current design can only operate on conjugator priors based on normal likelihood, we would 
like to extend both current two-stage design and multi-stage design to accommodate non-
conjugate priors. To do this, we will utilize the WinBUGS software and the R package 
R2WinBUGS to handle non-conjugate priors [81, 82]. Further, we only explored situations 
where the continuous outcome follows a normal distribution. However, as mentioned 
above, it may not be realistic in practice. Thus, we plan to explore other distributions for 
the continuous endpoints. Second, in practice, the likelihood variance may not be known 
in advance, we would like to incorporate the likelihood variance as an unknown parameter 
into the design.  Third, the current design is best for the short-term endpoints, which can 
be evaluated without affecting the continuous process of patients’ recruitment. However, 
this design may not be appropriate for those endpoints that need longer time to be obtained 
and evaluated. Recently, with the development of immunotherapy in oncology, there are 
several proposed designs taking into the treatment lagged time effect for the survival 
endpoints [83-85]. One future direction is to incorporate time factor or delayed treatment 
effect into the design for the continuous endpoints. Another possible future direction is 
evaluate this continuous endpoint and survival outcome simultaneously, which may be 
more interesting in terms of clinical impact. 
Lastly, we also plan to optimize and update the searching strategy in the future. For 
the multi-stage design described in chapter 3, the current version only allows searching for 
a range of 𝑃𝑇 for the minimax design. We would like to optimize the searching strategy to 
allow 𝑃𝐿 and 𝑃𝑈 search as well as the optimal design output. In addition, due to the current 
algorithm, we can only accommodate up to 40 stages during the trial due to the dependency 
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of the cubature package [77]. We would like to expand it into continuous monitoring 
without limitation.  
In conclusion, we developed two predictive probability interim designs for 
continuous endpoints and an R package to implement in this dissertation. The two designs 
are flexible and well preserve statistical properties. It provides an alternative option for 
continuous endpoints when a single-arm design with flexible interim stopping is desired. 
As research rapidly moves to incorporate more immunotherapies and targeted therapies, 
these designs will accommodate new types of outcomes while allowing for flexible 
stopping rules for futility and/or efficacy to continue optimizing trial resources and 
prioritize agents with compelling early phase data.  
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APPENDICES 
A1 Transformations from binary endpoints (𝒑) to continuous endpoints 
(𝜇)[5] (From Wason et al., 2011).  
Let 𝑝0 denote the response rate under the null hypothesis and 𝑝1 denote 
the response rate under the alternative hypothesis. 𝜇0 is the tumor shrinkage 
under the null hypothesis and 𝜇1 is under the alternative hypothesis. 𝜎 is the 
standard deviation of the continuous endpoint, which is assumed to be known. 
𝑑 is the cut-off the ratio of dichotomization, which is 30% with RECIST criteria 
[1]. 𝑋 is denoted as the random variable for the continuous endpoint, such as 
tumor shrinkage. 𝑍 is the standard normal random variable. 
𝑝0 = Pr(𝑋 > 𝑑) = Pr(𝜎𝑍 + 𝜇0 > 𝑑) = 1 −  𝛷(
𝑑 − 𝜇0 
𝜎
) 
So that:  
𝜇0 = 𝑑 −  𝜎𝛷
−1(1 − 𝑝0) 
Similarly,  
𝜇1 = 𝑑 −  𝜎𝛷
−1(1 − 𝑝1) 
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A2 Frequentist operating characteristics calculation for two-stage design 
to terminate early for efficacy. 
If the investigators prefer to terminating the trial early for both futility and efficacy, we 
can rewrite the 𝜑(∙)  in chapter one in the form of rejecting the null hypothesis at each 
stage. We denote it as 𝜑∗(∙). Thus,  
𝜑∗(𝜇0, 𝜎, 𝑛1 , 𝑛2 , ?̅?𝑛1 , ?̅?𝐿, ?̅?𝑈, ?̅?𝐿
′) = 𝑃𝜇(?̅?𝑛1 ≥ ?̅?𝑈) + ∫ 𝑓𝜇(𝑥)𝑃𝜇(?̅?𝑛1+𝑛2 ≥ ?̅?𝑈
′ )
?̅?𝑈
 ?̅?𝐿
𝑑𝑥 
 
Similar as 𝜑(. ), the first part of 𝜑∗(. ) is the probability of rejecting the null hypothesis at 
the first stage and the second part if the probability of rejecting the null at the end of 
second stage.  
The corresponding type I and type II error rates can be written as: 
𝛼 = 𝜑∗(𝜇0, 𝜎, 𝑛1 , 𝑛2 , ?̅?𝑛1 , ?̅?𝐿, ?̅?𝑈, ?̅?𝐿
′)          
𝛽 = 1 − 𝜑∗(𝜇1, 𝜎, 𝑛1 , 𝑛2 , ?̅?𝑛1 , ?̅?𝐿 , ?̅?𝑈, ?̅?𝐿
′) 
The probability of early termination under the null hypothesis is : 
𝑃𝐸𝑇(𝜇0) =  𝑃𝜇(?̅?𝑛1 ≤ ?̅?𝐿|𝐻0) + 𝑃𝜇(?̅?𝑛1 ≥ ?̅?𝑈|𝐻0) 
And the expected sample size under the null hypothesis is the same as the situation for 
only stopping early for futility. 
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A3 Supplementary simulation results for two-stage designs. 
Table A3.1 Optimal two-stage design stopping early for futility 
Table A3.2 Minimax two-stage design stopping early for futility 
Table A3.3 Optimal two-stage design stopping early for efficacy 
Table A3.4 Minimax two-stage design stopping early for efficacy 
Table A3.5 Operating characteristics of optimal efficacy designs with different priors. 
Table A3.6 Operating characteristics of minimax efficacy designs with different priors. 
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Table A3.1 Operating characteristics of optimal two-stage design for continuous endpoints with early termination for futility. For both 
designs below, 𝑃𝑈 = 1, μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with type 
I and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
 Optimal Design 
Effect size σ 𝑃𝑇 𝑃𝐿 Nmax 𝑛1 ?̅?𝐿  ?̅?𝐿
′  PET En Type I Error Type II Error 
1.0 10.0 0.945 0.100 7 3 21.49 26.46 0.60 4.59 0.040 0.199  
 0.937 0.100 9 4 20.98 25.38 0.58 6.11 0.050 0.099 
0.9 11.1 
11 
0.936 0.094 8 3 20.25 26.34 0.52 5.42 0.049 0.200 
  0.939 0.094 11 5 20.89 25.41 0.57 7.58 0.050 0.100 
0.8 12.5 0.938 0.100 10 5 21.67 26.38 0.62 6.91 0.050 0.199  
 0.941 0.096 14 6 20.63 25.41 0.55 9.60 0.050 0.100 
0.7 14.3 0.941 0.085 13 6 20.85 26.43 0.56 9.09 0.050 0.200 
  0.943 0.085 18 9 21.01 25.47 0.58 12.74 0.050 0.100 
0.6 16.7 0.942 0.100 18 7 20.30 26.34 0.52 12.29 0.050 0.199 
  0.944 0.099 25 10 20.31 25.40 0.52 17.15 0.049 0.100 
0.5 20.0 0.945 0.100 26 11 20.69 26.39 0.55 17.81 0.048 0.199  
 0.945 0.100 36 15 20.46 25.40 0.54 24.76 0.049 0.099 
0.4 25.0 0.945 0.098 40 17 20.57 26.40 0.54 27.65 0.050 0.200 
  0.946 0.100 56 24 20.54 25.42 0.54 38.65 0.049 0.100 
0.3 33.3 0.946 0.099 71 31 20.68 26.40 0.55 49.49 0.050 0.200 
  0.946 0.100 99 42 20.45 25.41 0.54 68.52 0.050 0.100 
0.2 50.0 0.947 0.100 160 71 20.77 26.41 0.55 110.93 0.049 0.200  
 0.947 0.100 223 96 20.51 25.42 0.54 154.48 0.050 0.100 
0.1 100    0.947 0.100 638 279 20.66 26.41 0.51 442.83 0.050 0.200 
  0.947 0.100 890 382 20.47 25.42 0.54 617.33 0.050 0.100 
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Table A3.2 Operating characteristics of minimax two-stage design for continuous endpoints with early termination for futility. For both 
designs below, 𝑃𝑈 = 1,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with type 
I and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
 
Minimax Design 
Effect 
size 
σ PT PL N.max n1 ?̅?𝐿  ?̅?𝐿
′  PET En Type I 
Error 
Type II 
Error 
1.0 10.0 0.945 0.100 7 3 21.49 26.46 0.60 4.59 0.040 0.199 
  0.937 0.100 9 4 20.98 25.38 0.58 6.11 0.050 0.099 
0.9 11.1 
11 
0.947 0.031 8 1 6.11 26.74 0.11 7.26 0.042 0.189 
  0.938 0.058 11 3 17.07 25.38 0.32 8.41 0.049 0.096 
0.8 12.5 0.938 0.100 10 5 21.67 26.38 0.62 6.91 0.050 0.199 
  0.941 0.096 14 6 20.63 25.41 0.55 9.60 0.050 0.100 
0.7 14.3 0.945 0.044 13 7 20.53 26.57 0.54 9.77 0.047 0.200 
  0.952 0.001 16 3 1.95 26.13 0.01 15.81 0.043 0.089 
0.6 16.7 0.941 0.063 18 6 18.04 26.31 0.39 13.36 0.050 0.188 
  0.942 0.046 24 7 16.63 25.46 0.30 18.96 0.050 0.099 
0.5 20.0 0.945 0.080 25 18 23.09 26.52 0.74 19.79 0.050 0.200 
  0.946 0.069 35 18 20.72 25.51 0.56 25.47 0.050 0.100 
0.4 25.0 0.940 0.055 39 14 17.85 26.30 0.37 29.66 0.050 0.189 
  0.945 0.002 53 23 14.25 25.54 0.14 48.95 0.047 0.097 
0.3 33.3 0.941 0.069 69 24 18.23 26.32 0.40 51.12 0.050 0.194 
  0.950 0.010 96 59 19.37 25.62 0.44 79.62 0.049 0.100 
0.2 50.0 0.949 0.080 155 149 25.46 26.59 0.91 149.55 0.050 0.200 
  0.948 0.081 217 146 22.23 25.53 0.70 166.95 0.050 0.100 
0.1 100 0.943 0.006      591 282 15.69 26.51  0.23 518.48 0.049 0.199 
  0.944 0.017 858 265 16.64 25.46 0.29 684.80 0.049 0.099 
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Table A3.3 Operating characteristics of optimal two-stage design for continuous endpoints with early termination for efficacy. For both 
designs below, 𝑃𝑈 = 0.95,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is with 
type I and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
 
 Optimal Design 
Effect size σ 𝑃𝑇 𝑃𝐿 Nmax 𝑛1 ?̅?𝐿  ?̅?𝑈 PET 𝐸𝑛 Type I Error Type II Error 
1.0 10.0 0.946 0.100 7 3 21.54 35.33 0.61 4.57 0.041 0.200  
 0.940 0.088 9 4 20.80 32.65 0.57 6.15 0.050 0.100 
0.9 11.1 
11 
0.938 0.100 8 4 21.82 33.93 0.63 5.46 0.050 0.198 
  0.942 0.094 11 6 21.72 31.08 0.66 25.5 0.050 0.100 
0.8 12.5 0.942 0.073 10 5 21.11 33.90 0.59 7.08 0.049 0.200  
 0.944 0.093 14 7 21.30 31.54 0.62 9.69 0.050 0.100 
0.7 14.3 0.949 0.100 14 5 20.29 36.16 0.52 9.29 0.045 0.200 
  0.948 0.100 19 7 20.21 33.29 0.52 12.74 0.048 0.100 
0.6 16.7 0.946 0.088 18 8 20.78 34.37 0.56 12.40 0.050 0.200 
  0.947 0.099 25 12 21.17 31.55 0.60 17.15 0.050 0.100 
0.5 20.0 0.947 0.100 26 12 21.20 33.86 0.59 17.74 0.050 0.199  
 0.948 0.100 36 18 21.31 31.20 0.62 24.87 0.050 0.099 
0.4 25.0 0.949 0.100 41 17 20.64 36.44 0.55 27.79 0.050 0.199 
  0.950 0.100 57 24 20.59 32.09 0.56 38.69 0.050 0.100 
0.3 33.3 0.950 0.095 72 33 20.97 33.69 0.58 49.56 0.050 0.200 
  0.951 0.100 101 45 20.81 31.71 0.57 68.65 0.049 0.100 
0.2 50.0 0.951 0.100 163 72 20.89 33.82 0.57 111.20 0.050 0.200  
 0.951 0.100 226 103 20.87 31.54 0.58 154.66 0.050 0.100 
0.1 100 0.952 0.100 656 273 20.59 34.13 0.55 446.01 0.050 0.200 
       0.952           0.100 
   0.`00 
910 398 20.71 31.72 0.57 620.32 0.050 0.100 
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Table A3.4 Operating characteristics of minimax two-stage design for continuous endpoints with early termination for efficacy. For 
both designs below,  𝑃𝑈 = 0.95,  μ0 = 20,  μ1 = 30, θ = μ0 = 20, σ = 10, 12.5, 20 and 50, τ =  σ. The first row for each effect size is 
with type I and type II error rate constraints (α, β) = (0.05, 0.2) and the second row for each effect size is with (α, β) = (0.05, 0.1).  
 
 Minimax Design 
Effect size σ 𝑃𝑇 𝑃𝐿 Nmax 𝑛1 ?̅?𝐿 ?̅?𝑈 PET 𝐸𝑛 Type I Error Type II Error 
1.0 10.0 0.936 0.100 7 3 21.13 34.93 0.58 4.67 0.050 0.176  
 0.942 0.072 9 4 20.44 32.72 0.54 6.30 0.048 0.100 
0.9 11.1 
11 
0.938 0.100 8 4 21.82 33.93 0.63 5.46 0.050 0.198 
  0.947 0.037 11 6 20.40 31.25 0.54 8.29 0.047 0.100 
0.8 12.5 0.941 0.100 10 6 22.61 32.34 0.70 7.19 0.050 0.200  
 0.944 0.093 14 7 21.30 31.54 0.62 9.69 0.050 0.100 
0.7 14.3 0.945 0.059 13 7 21.07 33.19 0.59 9.49 0.049 0.200 
  0.945 0.094 18 11 22.12 30.21 0.70 13.12 0.050 0.100 
0.6 16.7 0.945 0.100 18 10 22.13 32.62 0.67 12.68 0.050 0.196 
  0.946 0.100 24 21 23.96 27.73 0.88 21.36 0.050 0.100 
0.5 20.0 0.948 0.030 25 17 21.55 31.31 0.64 19.92 0.050 0.200  
 0.949 0.052 35 20 20.91 30.59 0.59 26.15 0.050 0.100 
0.4 25.0 0.949 0.034 39 29 22.38 30.57 0.71 31.93 0.050 0.200 
  0.948 0.100 54 47 23.91 27.76 0.88 47.88 0.050 0.100 
0.3 33.3 0.949 0.056 69 61 24.31 29.01 0.86 62.11 0.050 0.200 
  0.651 0.014 96 65 20.51 29.56 0.56 78.65 0.050 0.100 
0.2 50.0 0.950 0.030 155 140 24.16 28.80 0.86 142.16 0.050 0.200  
 0.951 0.003 215 172 20.97 25.66 0.61 188.60 0.050 0.100 
0.1 100 0.950 0.046 619 596 25.29 27.92 0.93 597.65 0.050 0.200 
  0.950 0.045 857 837 24.73 26.49 0.94 838.11 0.050 0.100 
  
 
1
0
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Table A3.5 Operating characteristics of optimal efficacy designs with different priors. (Design parameter: μ0 = 20, μ1 = 30, α =
 0.05, β = 0.2, σ = 20)  
 
Prior 
N(𝜃, 𝜏2) 
𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿  ?̅?𝑈 PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
      𝑁(20, 202)        0.947 0.100 26 12 21.20 33.86 0.59 17.74 0.050 0.199 
   𝑁(20, 8.942) 0.931 0.096 26 11 21.15 36.07 0.58 17.31 0.050 0.200 
𝑁(30, 202) 0.958 0.100 26 12 20.83 33.49 0.58 18.07 0.050 0.200 
  𝑁(30, 8.942) 0.977 0.100 26 13 20.66 33.03 0.56 18.76 0.048 0.200 
 
 
 
 
Table A3.6 Operating characteristics of minimax efficacy designs with different priors. (Design parameter: μ0 = 20, μ1 = 30, σ =
20, α =  0.05, β = 0.2)  
 
Prior 
N(𝜃, 𝜏2) 
𝑃𝑇 𝑃𝐿 𝑁𝑚𝑎𝑥 𝑛1 ?̅?𝐿  ?̅?𝐿
′  PET 𝐸𝑛 Type I 
Error 
Type II 
Error 
      𝑁(20, 202)        0.948 0.030 25 17 21.55 31.31 0.64 19.92 0.050 0.200 
   𝑁(20, 8.942) 0.935 0.013 25 16 20.27 32.42 0.53 20.25 0.049 0.200 
𝑁(30, 202) 0.957 0.068 25 20 23.58 29.88 0.80 20.99 0.050 0.200 
  𝑁(30, 8.942) 0.975 0.100 25 21 24.21 29.40 0.85 21.61 0.050 0.200 
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A4 Supplementary simulation results for multi-stage designs. 
Table A4.1 Operating characteristics of Minimax multi-stage design for continuous 
endpoints. For both designs below,  μ0  = 20,  μ1  = 30,  θ = μ0 = 20 , σ =
10, 12.5, 20 and 50, τ =  σ. 𝑃𝐿 = 0.1 and 𝑃𝑈 = 0.95.  
𝛼 = 0.05, 𝛽 = 0.1 
Effect 
size
σ 𝐾 𝑃𝑇 N.max Type I Error Type II Error 
1.0 10 3 0.940 10 0.050 0.081 
4 0.940 11 0.050 0.076 
5 0.940 11 0.049 0.088 
6 0.940 11 0.049 0.087 
7 0.942 13 0.050 0.070 
8 0.943 15 0.048 0.051 
9 0.941 17 0.050 0.044 
10 0.969 12 0.017 0.071 
0.8 12.5 3 0.945 16 0.049 0.078 
4 0.945 17 0.049 0.084 
5 0.960 18 0.037 0.096 
6 0.947 18 0.049 0.084 
7 0.947 19 0.049 0.080 
8 0.950 17 0.048 0.088 
9 0.950 20 0.048 0.093 
10 0.929 21 0.049 0.080 
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Table A4.1 (continued)  
𝛼 = 0.05, 𝛽 = 0.1 
Effect 
size 
σ 𝐾 𝑃𝑇 N.max Type I Error Type II Error 
0.5 20 3 0.950 38 0.049 0.098 
  4 0.952 41 0.049 0.097 
  5 0.953 43 0.049 0.098 
  6 0.954 45 0.049 0.089 
 
 7 0.955 46 0.050 0.096 
  8 0.956 48 0.049 0.095 
  9 0.957 50 0.047 0.099 
  10 0.951 52 0.046 0.036 
0.2 50 3 0.953 237 0.050 0.100 
 
 4 0.955 252 0.050 0.099 
  5 0.957 263 0.050 0.098 
  6 0.960 274 0.049 0.100 
  7 0.961 291 0.050 0.094 
  8 0.970 295 0.043 0.090 
  9 0.963 296 0.049 0.089 
  10 0.965 310 0.049 0.044 
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A5. Calculation of covariance between ?̅?𝒏𝒊 and ?̅?𝒏𝒋: 
Let 𝑛𝑖 denote the cumulative number of patients at i
th stage and 𝑛𝑗  denote the cumulative 
sample size at jth stage, where 𝑛𝑗 > 𝑛𝑖. Thus,  ?̅?𝑛𝑖 denotes the average tumor shrinkage 
from the 𝑛𝑖 patients and ?̅?𝑛𝑗 denotes the average tumor shrinkage from the 𝑛𝑗  patients.  
𝐶𝑜𝑣(?̅?𝑛𝑖 , ?̅?𝑛𝑗) = 𝐶𝑜𝑣 (
1
𝑛𝑖
∑ 𝑋𝑖
𝑛𝑖
𝑖=1  ,
1
𝑛𝑗
∑ 𝑋𝑗
𝑛𝑗
𝑗=1  ) 
= 𝐸(
1
𝑛𝑖
∑𝑋𝑖
𝑛𝑖
𝑖=1
∗  
1
𝑛𝑗
∑𝑋𝑗
𝑛𝑗
𝑗=1
) − 𝐸 (
1
𝑛𝑖
∑𝑋𝑖
𝑛𝑖
𝑖=1
)𝐸 (
1
𝑛𝑗
∑𝑋𝑗
𝑛𝑗
𝑗=1
) 
                             =
1
𝑛𝑖𝑛𝑗
 𝐸 (∑ 𝑋𝑖
𝑛𝑖
𝑖=1 ∑ 𝑋𝑗
𝑛𝑗
𝑗=1 ) − 𝜇
2                              
                             =
1
𝑛𝑖𝑛𝑗
𝐸 (𝑛𝑖?̅?𝑛𝑖𝑛𝑗?̅?𝑛𝑗) − 𝜇
2 
                             =  
1
𝑛𝑖𝑛𝑗
𝐸 [𝑛𝑖?̅?𝑛𝑖 ∗ (𝑛𝑖?̅?𝑛𝑖 + (𝑛𝑗 − 𝑛𝑖  )?̅?′𝑛𝑗)] −  𝜇
2 
                                =
1
𝑛𝑖𝑛𝑗
𝐸 [𝑛𝑖
2?̅?𝑛𝑖
2 + 𝑛𝑖?̅?𝑛𝑖(𝑛𝑗 − 𝑛𝑖 )?̅?𝑛𝑗
′  ] −  𝜇2         
                                =
𝑛𝑖
2
𝑛𝑖𝑛𝑗
𝐸[?̅?𝑛𝑖
2 ] + 
𝑛𝑖(𝑛𝑗 − 𝑛𝑖  )
𝑛𝑖𝑛𝑗
𝐸(?̅?𝑛𝑖?̅?𝑛𝑗
′ ) − 𝜇2    
Since 𝐸[?̅?𝑛𝑖
2 ] = 𝑉𝑎𝑟(?̅?𝑛𝑖) + [𝐸(?̅?𝑛𝑖)]
2, ?̅?𝑛𝑖  and ?̅?𝑛𝑗
′  are independent with both mean 𝜇, 
where ?̅?𝑛𝑗
′  is the average tumor shrinkage from the patients 𝑛𝑗 − 𝑛𝑖. 
𝐶𝑜𝑣(?̅?𝑛𝑖 , ?̅?𝑛𝑗) = 
𝑛𝑖
2
𝑛𝑖𝑛𝑗
(𝑉𝑎𝑟(?̅?𝑛𝑖) + [𝐸(?̅?𝑛𝑖)]
2) + 
𝑛𝑖(𝑛𝑗−𝑛𝑖 )
𝑛𝑖𝑛𝑗
𝐸(?̅?𝑛𝑖)𝐸 (?̅?𝑛𝑗
′ ) − 𝜇2 
                         =
𝑛𝑖
2
𝑛𝑖𝑛𝑗
(
𝜎2
𝑛𝑖
+ 𝜇2 ) + 
𝑛𝑖(𝑛𝑗−𝑛𝑖 )
𝑛𝑖𝑛𝑗
 𝜇2 − 𝜇2 
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                            =  
𝜎2
𝑛𝑗
+
𝑛𝑖
2
𝑛𝑖𝑛𝑗
𝜇2 + 𝜇2 −
𝑛𝑖
2
𝑛𝑖𝑛𝑗
𝜇2 − 𝜇2  =  
𝜎2
𝑛𝑗
 
Calculation of covariance between 𝒁𝒏𝒊 and 𝒁𝒏𝒋 from ?̅?𝒏𝒊 and ?̅?𝒏𝒋 
𝑍𝑛𝑖 = 
?̅?𝑛𝑖− 𝜇
√𝜎2/𝑛𝑖
  and 𝑍𝑛𝑗 = 
?̅?𝑛𝑗− 𝜇
√𝜎2/𝑛𝑗
 
𝐶𝑜𝑣(𝑍𝑛𝑖 , 𝑍𝑛𝑗) = 𝐶𝑜𝑣
(
 
 ?̅?𝑛𝑖− 𝜇
√
𝜎2
𝑛𝑖
 ,   
?̅?𝑛𝑗− 𝜇
√
𝜎2
𝑛𝑗
 
)
 
 
= 𝐸
(
 
 ?̅?𝑛𝑖− 𝜇
√
𝜎2
𝑛𝑖
∗
?̅?𝑛𝑗− 𝜇
√
𝜎2
𝑛𝑗
 
)
 
 
− 𝐸(
?̅?𝑛𝑖− 𝜇
√
𝜎2
𝑛𝑖
)𝐸(
?̅?𝑛𝑗− 𝜇
√
𝜎2
𝑛𝑗
) 
    =  
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [(?̅?𝑛𝑖 −  𝜇) (?̅?𝑛𝑗 −  𝜇)] − 
√𝑛𝑖𝑛𝑗
𝜎2
𝐸[?̅?𝑛𝑖 −  𝜇]𝐸 [?̅?𝑛𝑗 −  𝜇] 
                        = 
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [?̅?𝑛𝑖?̅?𝑛𝑗 − 𝜇 (?̅?𝑛𝑖 + ?̅?𝑛𝑗) + 𝜇
2 ] − 0  
                           =  
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [?̅?𝑛𝑖?̅?𝑛𝑗] −  
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [𝜇 (?̅?𝑛𝑖 + ?̅?𝑛𝑗)] +
√𝑛𝑖𝑛𝑗
𝜎2
𝐸[𝜇2] 
                          =  
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [?̅?𝑛𝑖 ∗  
1
𝑛𝑗
∑𝑋𝑗
𝑛𝑗
𝑗=1
] −
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [𝜇 (?̅?𝑛𝑖 + ?̅?𝑛𝑗)] +
√𝑛𝑖𝑛𝑗
𝜎2
𝐸[𝜇2] 
                          =  
√𝑛𝑖𝑛𝑗
𝜎2
1
𝑛𝑗
𝐸 [?̅?𝑛𝑖 (𝑛𝑖?̅?𝑛𝑖 + (𝑛𝑗 − 𝑛𝑖 )?̅?′𝑛𝑗)] −
√𝑛𝑖𝑛𝑗
𝜎2
𝐸 [𝜇 (?̅?𝑛𝑖 + ?̅?𝑛𝑗)]
+
√𝑛𝑖𝑛𝑗
𝜎2
𝐸[𝜇2] 
               =
1
𝜎2
√
𝑛𝑖
𝑛𝑗
𝐸 [𝑛𝑖?̅?𝑛𝑖
2 + (𝑛𝑗 − 𝑛𝑖  )?̅?𝑛𝑖?̅?′𝑛𝑗  ] −  
√𝑛𝑖𝑛𝑗
𝜎2
𝜇𝐸 [?̅?𝑛𝑖 + ?̅?𝑛𝑗] +
√𝑛𝑖𝑛𝑗
𝜎2
 𝜇2 
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          =
𝑛𝑖
𝜎2
√
𝑛𝑖
𝑛𝑗
 𝐸[?̅?𝑛𝑖
2 ] +
1
𝜎2
√
𝑛𝑖
𝑛𝑗
𝐸 [(𝑛𝑗 − 𝑛𝑖  )?̅?𝑛𝑖?̅?′𝑛𝑗] −   2
√𝑛𝑖𝑛𝑗
𝜎2
𝜇2 + 
√𝑛𝑖𝑛𝑗
𝜎2
 𝜇2 
                 =
𝑛𝑖
𝜎2
√
𝑛𝑖
𝑛𝑗
 (𝑉𝑎𝑟(?̅?𝑛𝑖) + [𝐸(?̅?𝑛𝑖)]
2
) + 
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2 par2stage
par2stage Find the optimal and minimax two-stage design based on predictive
probability
Description
This function allows the user to search for the optimal and minimax predictive probability design for
continuous normal endpints in a single-arm two-stage clinical trial setting. "sigma" is the standard
deviation for the likelihood function. "tau" is the standard deviation for normal prior distribnution.
Both "sigma" and "tau" need input from the investigators and usually should be obtained from the
historical control or standard therapy. The ratio of "sigma" to "tau" is related to the effective sample
size for the prior.
Usage
par2stage(sigma, tau, theta, mu0, mu1, pTlow, pThigh, pTby, pLlow, pLhigh, pLby,
pU, pre.typeIerror, pre.typeIIerror)
Arguments
sigma The standard deviation from the user pre-specified normal likelihood function.
It should be obtained from previous historical control or standard therapy.
tau The standard deviation from the user pre-specified normal prior distribution. It
should be input from the clinical investigators.
theta The mean from the user pre-specified normal prior distributions.It should be
input from the clinical investigators.
mu0 The maximum uninteresting mean from the null hypothesis.
mu1 The minimum interesting mean from the alternative hypothesis.
pTlow The lower boundary for searching range of pT. pT is usually a large probability
above 0.8. If the searching range for pT is 0.9 to 0.99, pTlow = 0.9.
pThigh The higher boundary for searching range of pT. pT is usually a large probability
above 0.8. If the searching range for pT is 0.9 to 0.99, pThigh = 0.99.
pTby The searching increment for pT. The default value is 0.01.
pLlow The lower boundary for searching range of pL. pL is usually a small probability
below 0.1. If the searching range for pL is 0.01 to 0.1, pLlow = 0.01.
pLhigh The higher boundary for searching range of pL. pL is usually a small probability
below 0.1. If the searching range for pL is 0.01 to 0.1, pLhigh = 0.1.
pLby The searching increment for pL. The default value is 0.01.
pU The efficacy boundary for predictive probability. It is a value usually above 0.9.
pre.typeIerror The user pre-specified nominal type I error rate constraint. The default value is
0.05.
pre.typeIIerror
The user pre-specified nominal type II error rate constraint.The default value is
0.2.
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Value
Returns the operating characteristics of two-stage optimal and minimax designs
Total Sample Size
Total sample size for the two stages
Sample Size for the First Stage
The number of patients required in the first stage
Futility Boundaries at the End of the First Stage
A value under which to stop the trial early for futility at the end of the first stage
Futility Boundaries at the End of the Second Stage
A value under which to claim the trial unsuccessful
Efficacy Boundaries at the End of the First Stage
A value above which to stop the trial early for efficacy at the end of the first
stage
Efficacy Boundaries at the End of the Second Stage
A value above which to claim the trial successful
Probability of Early Termination
Probability of early termination under the null hypothesis
Expected Sample Size under H0
Expected sample size under the null hypothesis
Type I Error The Actual type I error rate
Type II Error The Actual type II error rate
pT The actual pT yeilding the desired design
pL The actual pL yeilding the desired design
Plot The plot containing stopping boundaries
Examples
#Example 1: a two-stage design with mu0 = 20 and mu1 = 30 and stop the trial early
only for futility
par2stage (sigma = 20, tau = 20, theta = 20, mu0 = 20, mu1 = 30,pTlow = 0.9, pThigh = 0.99,
pTby = 0.01,pLlow = 0.01, pLhigh = 0.1, pLby = 0.01, pU = 1, pre.typeIerror = 0.05,
pre.typeIIerror = 0.2)
#Example 2: a two-stage design with mu0 = 20 and mu1 = 30 and stop the trial early
for both futility and efficacy
par2stage (sigma = 20, tau = 20, theta = 20, mu0 = 20, mu1 = 30, pTlow = 0.9, pThigh = 0.99,
pTby = 0.01,pLlow = 0.01, pLhigh = 0.1, pLby = 0.01, pU = 0.95, pre.typeIerror = 0.05,
pre.typeIIerror = 0.2)
parmultistage Find the minimax multi-stage design based on predictive probability
and plot the stopping boundaries
Description
This function performs a grid search for the minimax design in a single-arm multi-stage setting.There
are many different user-defined options in this function, which allows for different group sizes and
choosing continuously monitoring.
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Usage
parmultistage(continuous, first.look, num.interim, equal.spaced, user.p, sigma,
tau, mu0, mu1, theta, pTlow, pThigh, pTby, pL, pU, pre.typeIerror,
pre.typeIIerror, plot_yes)
Arguments
continuous The option to choose continuous monitoring or not. The default value is F,
representing "no continuous monitoring"
first.look The proportion of the total sample size before the continuously monitoring. The
default value is NULL. It should have a value if the value for "continuous" equals
to T.
num.interim The number of interim looks involved in the trial. The user should specify a
value up to 40 if the same sample size at each stage is preferred. That is, when
eqaul.spaced = T.
equal.spaced The option to choose if the same sample size at each stage is required. If so, the
value is set as T. Otherwise, equal.spaced = F.
user.p When different sample sizes at each stage is desired, the user should specify the
cumulative proportion at the end of each stage. For example, if the user want to
conduct the interim analysis at 20 for user.p is c(0.2, 0.5, 0.8 , 1). If the same
sample size at each stage is desired, the value is NULL.
sigma The standard deviation from the user pre-specified normal likelihood function.
tau The standard deviation from the user pre-specified normal prior distribution.
mu0 The maximum uninteresting mean from the null hypothesis.
mu1 The minimum interesting mean from the alternative hypothesis.
theta The mean from the user pre-specified normal prior distribution.
pTlow The lower boundary for searching range of pT. pT is usually a large probability
above 0.8. If the searching range for pT is 0.9 to 0.99, pTlow = 0.9.
pThigh The higher boundary for searching range of pT. pT is usually a large probability
above 0.8. If the searching range for pT is 0.9 to 0.99, pThigh = 0.99.
pTby The searching increment for pT. The default value is 0.01.
pL The futility boundary for predictive probability. It is a value usually below 0.1.
pU The efficacy boundary for predictive probability. It is a value usually above 0.9.
pre.typeIerror The user pre-specified nominal type I error rate constraint. The default value is
0.05.
pre.typeIIerror
The user pre-specified nominal type II error rate constraint.The default value is
0.2.
plot_yes The option to choose if displaying the stopping boundary plot.
Details
parmultistage utilized the grid search strategy to implement the search in a user pre-specified range
for pT and identify the minimax design.
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Value
Returns the operating characteristics of the minimax design
Cumulative sample size for each interim look
A vector containing the cumulative sample size at the end of each stage for
interim analysis
Futility Boundaries
A vector containing the futility stopping boundaries for each interim look
Efficacy Boundaries
A vector containing the efficacy stopping boundaries for each interim look
Probability of Early Termination
Probability of early termination under the null hypothesis
Expected Sample Size under H0
Expected sample size under the null hypothesis
Type I Error The Actual type I error rate
Type II Error The Actual type II error rate
pT The actual pT yeilding the desired design
Plot The plot containing stopping boundaries
Examples
#Example 1 : Equal sample size at each interim look
parmultistage(continuous = F, first.look = NULL, num.interim = 2 , equal.spaced = T ,
user.p = NULL, sigma = 20, tau = 20, mu0 = 20, mu1 = 30 , theta = 20, pTlow = 0.9,
pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror = 0.05 ,
pre.typeIIerror = 0.2, plot_yes = T)
#Example 2: Unequal sample size for at each interim look
parmultistage(continuous = F, first.look = NULL, num.interim = 3, equal.spaced = F ,
user.p = c(0.1, 0.4, 0.8, 1.0),sigma = 20, tau = 20, mu0 = 20, mu1 = 30 , theta = 20,
pTlow = 0.9, pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror = 0.05 ,
pre.typeIIerror = 0.2, plot_yes = T)
#Exmaple 3: Continuouly monitor after 50% of sample size are enrolled
parmultistage(continuous = T, first.look = 0.5, num.interim = NULL, equal.spaced = F ,
user.p = NULL, sigma = 20, tau = 20, mu0 = 20, mu1 = 30 , theta = 20, pTlow = 0.9,
pThigh = 0.99, pTby = 0.01, pL = 0.1, pU = 0.95, pre.typeIerror = 0.05 ,
pre.typeIIerror = 0.2, plot_yes = T)
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